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Abstract 
 
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer and 
accounts for 30 - 35% of all cancers in children. Significant improvement in the treatment 
of pediatric ALL has been achieved in recent years. Only 50 years ago, the disease was 
uniformly fatal with an Overall Survival (OS) rate < 5%.  Modern-day, multi-drug 
chemotherapy is associated with an overall survival rate over 80%. Standard-risk ALL 
comprises the majority of ALL with an overall survival approaching 90%. Despite this 
success, children who relapse from this disease accounts for the majority of cancer-
related deaths in children. The backbone of treatment protocols have incorporated 
somatic but not host genetic features in the treatment regimens. The current study 
examined 12 genetic polymorphisms affecting the pharmacodynamics of antileukemic 
drugs in an attempt to identify biologic markers related to the risk of disease relapse.  
In the current research program, 125 standard-risk ALL patients who were treated 
at The Children’s Hospital were enrolled in a retrospective study. Statistical analysis was 
performed to evaluate the association between genetic polymorphisms and risk of disease 
relapse in this study cohort. The GSTM1 null genotype was associated with a decreased 
risk of disease relapse (HR = 0.394, 95% CI = 0.127 - 1.224, P = 0.107). A combination 
analysis of the GSTM1 and GSTT1 genotypes revealed a stronger association between the 
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both the GSTM1 and GSTT1 normal genotype and an increased risk of leukemia relapse 
(HR = 2.73, 95% CI = 0.9 – 7.9, P = 0.063), compared with patients having either the 
GSTM1 or GSTT1 null genotype. A “drug exposure” model was used in this study. The 
risk of relapse in individual with a low or intermediate “drug exposure” genotype 
increased 2.4-fold (HR = 2.39, 95% CI = 0.8 – 6.9, P = 0.107) compared with the high 
“drug exposure” genotype. No significant associations with relapse were observed for the 
CYP1A1, CYP2B6, CYP3A4, CYP3A5, MTHFR C667T, MTHFR A1298G, or TYMS 
polymorphisms. The findings from this single institution study suggest that 
polymorphisms within genes of the GST superfamily may influence the treatment 
outcome in standard-risk ALL. They also point to the need of prospective, large multi-
institutional studies to validate these findings prior to clinical implementation. 
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Chapter 1 
 
 Introduction 
 
 
The successful treatment of childhood acute lymphoblastic leukemia represents 
one of the great medical accomplishments of the 20th century. Only five decades ago this 
disease was uniformly fatal. Since the introduction of multi-drug chemotherapy, the cure 
rate has risen to over 80%. In fact, the most recent results from the patients with ALL 
enrolled in Children’s Oncology Group (COG) protocols showed an improvement in the 
5-year overall survival rate from 83.6% to 90.3% over the last decade (Friedrich 2009). 
This success reflects the use of risk-directed therapy in which clinical variables related to 
the patient (e.g., age and leukocyte count at initial diagnosis) and biological variables 
specific to the leukemic cell population (e.g., DNA ploidy, ETV6/RUNX1 chromosomal 
translocation and Philadelphia chromosome) were used to stratify treatment (Sather 1986, 
Crist 1986, Seeger 1998, Heerema 2000). Unfortunately, ALL continues to be the leading 
cause of cancer-associated death in children despite improved treatment regimens. 
Moreover, the cure rate in patients who experience disease relapse has not improved over 
the past decade. Due to drug toxicity, simple increases in chemotherapeutic drug doses to 
decrease the relapse rate do not represent a viable solution. As seen in the most recent 
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COG protocols, the therapeutic limits of these toxic drugs have already been maximized 
(Landier 2008). Additionally, the long-term consequences of relapsed ALL include 
secondary malignancies, growth retardation, and cognitive impairments. More than two-
thirds of ALL patients reported at least one adverse late effect, and half of those reported 
an event that was severe or life-threatening.  
In order to eradicate the leukemic cells, cytotoxic drugs typically have to be used 
at maximum dose intensity. These drugs are then administered as frequently as possible 
to discourage tumor regrowth. One of the greatest challenges of leukemia treatment, 
therefore, is to adjust the drug dose to achieve the desired therapeutic outcome while 
limiting toxicity. Drug dosages have been administered based on the patient’s body 
surface area or weight for decades. This practice, however, is not based on solid research 
studies and has not taken into consideration the patient’s renal and hepatic functions, 
bone marrow reserve, or concurrent medical conditions (Sawyer 2001). Great efforts 
have been focused on dosage adjustment, based on renal function, to attain a desired drug 
concentration in plasma or area under the concentration-time curve (AUC) – an important 
factor in determining the tissue exposure to the drug. The successes of this approach were 
exemplified by methotrexate (MTX) dose adjustment for pediatric ALL therapy. Relling 
(1999a) demonstrated that the therapeutic outcome was related to achieving a target MTX 
plasma concentration during high-dose therapy. Dose adjustment based on monitoring of 
steady-state MTX levels improved treatment outcome. On the other hand, genes encoding 
drug-metabolizing enzymes can influence the efficacy and toxicity of chemotherapy 
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(Evans 1999). Despite efforts to anticipate drug complications, however, 
chemotherapeutic agents have variable pharmacokinetics and toxicity in individual 
patients. The causes of this variability are not always clear but are thought to be related to 
interindividual differences in drug metabolism and drug interactions. 
Treatment outcome is dependent not only on chemotherapy used, but also on the 
underlying biology of the host. Thus, numerous important biologic and therapeutic 
questions remain to be answered in order to achieve the goal of curing every child with 
ALL. With the completion of Human Genome Project, comprehensive studies of genetic 
polymorphisms in drug-metabolizing enzyme genes and drug-target genes have become 
possible. This information may make it possible to better customize drug dosage levels 
and drug combinations for individual patients. Insights into the role of host genetic 
variations will likely further improve the treatment outcome by integrating 
pharmacodynamic and pharmacogenomic studies to individualizing treatment regimen 
for children with acute lymphoblastic leukemia. 
 
1.1. Hypotheses and specific aims 
1.1.1. Specific Aim 1   
To determine the genotypes of CYP1A1, CYP2B6, CYP3A4, CYP3A5, GSTT1, 
GSTP1, TYMS, and MTHFR genes from patient DNA samples. 
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1.1.2. Specific Aim 2   
To identify the genetic polymorphisms of those genes that influence the treatment 
outcome in standard-risk ALL patients. 
Hypothesis 1: Variations in the drug-metabolism genes, individually or in combination, 
will be associated with the treatment outcome in standard-risk ALL patients. 
Hypothesis 2: Variations in the drug-target genes, individually or in combination, will be 
associated with the treatment outcome in standard-risk ALL patients. 
 
1.1.3. Specific Aim 3:  
To identify the possible association between the host genetic variation and 
ETV6/RUNX1 fusion transcript status in standard-risk ALL patients. 
Hypothesis: Host genetic variations (i.e., drug-metabolism and drug-target gene 
polymorphisms), individually or in combination, will be associated with ETV6/RUNX1 
fusion transcript status. 
These specific aims, taken together, represent a first step toward understanding the 
relationship between host genetic variations and treatment outcome in this clinically 
defined “homogeneous” group of patients.  
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1.2. Significance 
 
 
There is no doubt that host variation in the genes that encode drug-metabolizing 
enzymes and drug targets has the potential to alter drug serum concentration levels and 
molecular target engagement. The ultimate goal of pharmacogenetic studies is the 
individualization of drug dosage to each patient so as to achieve the maximum treatment 
efficacy while limiting toxicity. This study is significant for many reasons. First, this 
study will identify host genetic features that may affect the efficacy and toxicity of anti-
leukemic chemotherapy. Second, this study will obtain pertinent information regarding 
the potential association between genetic polymorphisms (alone or in combinations) and 
disease relapse in patients treated for pediatric standard-risk ALL. Third, this study may 
help to further refine risk-classification for pediatric ALL patients. This study represents 
a unique opportunity to provide data to further optimize treatment regimens for individual 
patients regardless of their presenting characteristics.   
Given the potential for genetic variation to influence patient response to drug 
treatment regimens, this work is particularly important in terms of its potential for 
improving the therapeutic outcome for children with lymphoblastic leukemia. 
Futhermore, this will be the first study conducted using a “homogeneous” cohort. 
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1.3. Outcome Measure(s) 
The primary outcome is to identify whether or not there exists an association 
between polymorphisms in the CYP1A1, CYP3A4/5, CYP2B6, GST, TYMS, and/or 
MTHFR genes and with treatment outcome (i.e., relapse vs. no relapse) for standard-risk 
ALL.  This study should be considered preliminary in nature due to the limited number of 
patients.  
The secondary outcome measures are to: 1) identify the frequencies of individual 
polymorphisms in the CYP1A1, CYP3A4/5, CYP2B6, GST, TYMS, and MTHFR genes in 
standard-risk ALL patients who carry the ETV6/RUNX1 fusion transcript; 2) explore the 
potential effects of combinations of genetic polymorphisms (or gene-gene interactions) 
on the treatment outcome of standard-risk ALL. 
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Chapter 2  
 
Background 
 
 
2.1. Acute Lymphoblastic Leukemia 
Leukemia or leukaemia (Greek leukos λευκός, "white"; aima αίμα, "blood") 
literally means “white blood” and is a cancer of the blood or bone marrow characterized 
by an abnormal increase of blood cells, usually leukocytes (white blood cells). It is part 
of the group of diseases categorized as hematological neoplasms. Depend on their 
progression, leukemias are usually divided into two major groups based on their clinical 
behavior.  These are: 1) Acute Leukemia, which progresses quickly with many immature 
white cells; and 2) Chronic Leukemia, which progresses slowly with more mature white 
cells (Pui 2006).  
Normally, the bone marrow contains self-renewing hematopoietic stem cells 
which develop into different types of mature blood cells including B lymphocytes, T 
lymphocytes, natural killer cells, various types of granulocytes, red blood cells, and 
platelets (Figure 2.1). ALL results from the clonal expansion of lymphoid cells arrested at 
an early stage of differentiation. ALL accounts for 75% of childhood leukemia cases with 
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an incidence of 3-4 children per 100,000 individuals. Thus, between 2500 and 3000 
children in the United States are diagnosed annually. ALL is the most common cancer in 
children representing about 25-35% of all childhood cancers and its diagnosis peaks 
between the ages of 2 and 5 years (Xie 2003). The incidence of the disease for this age 
group is approximately 4-fold higher than that for infants and is close to 10-fold higher 
than that for adolescents (ages 16 – 21 years) (Ries 2010). If leukemia is left untreated, it 
is uniformly fatal. A long list of often conflicting epidemiologic and environmental 
studies has attempted to elucidate the etiology of ALL. Two parallel infection-based 
hypothesis have been postulated based on an abnormal responses to infection; a peak in 
ALL incidence at 2-5 years of age; increased prevalence of the disease in the developed 
countries; and the presence of some geographical case clustering.  
Kinlen (2004) predicts that excess cases of childhood leukemia result from exposure to 
common but low-pathologic infections after population-mixing with carriers occurs. This 
hypothesis was supported by a U.S study (Wartenberg 2004) through US SEER data. 
However, other studies have shown higher incidence of ALL in urban or high-density 
regions (Li 1998, Hjalmars 1999, Adelman 2005). Greaves (2006) suggested a delayed-
infection hypothesis based on a two-hit model involving a delayed and dysregulated 
immune response to common infectious pathogens which leads to the transformation of 
pre-leukemic cells into acute lymphoblastic leukemia. So far, there is little evidence to 
support any role of viral transformation as a cause. Furthermore, it does not appear that 
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there is a single cause for childhood ALL – for most patients, a combination of factors 
appears necessary. Possible genetic causes of the disease will be discussed later. 
 
  
 
 
Figure 2.1 Blood cell development. Several steps are needed for a blood stem cell to 
become a red blood cell, platelet, or white blood cell. 
http://www.cancer.gov/cancertopics/pdq/treatment/childALL/HealthProfessional/ last 
accessed Nov. 20, 2010 
 
 
There are conflicting reports of factors that pose an increased risk for ALL, 
including parental occupation; maternal reproductive history; parental exposure to 
pesticides; and even exposures to high levels of residential electric and magnetic fields 
(Ahlbom 2000, Buffler 2005). Recurrent genetic abnormalities have also been observed 
in ALL patients, including chromosomal translocations that deregulate gene expression; 
chromosome copy number variations; and gene-specific mutations. The precise biological 
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and genetic mechanisms that lead to the development of ALL, however, remain 
unknown. Based on phenotypic observation and experimental models, however, it likely 
involves genes that control lymphoid cells differentiation, resulting in a clonal neoplastic 
disorder of the hematopoietic system. Recently, studies suggest that the etiology of ALL 
may be linked to a variety of genetic lesions in blood progenitor cells that are committed 
to differentiation or in some cases to lesions that arise in a hematopoietic stem cell (HSC) 
that has multi-lineage differentiation capacity The cellular microenvironment also 
appears to have an impact on leukemic cell transformation (Armstrong 2005, Wang 2005, 
Barabe 2007).  
 
2.2. Clinical Features 
 
 
The clinical presentation of ALL is often acute, although a small percentage of 
cases evolve slowly over several months (Pui 1998 and 2006). The common symptoms 
include fever, fatigue, bone or joint pain and bleeding. These presenting symptoms 
correlate with the uncontrolled growth of the malignant cell population invading the bone 
marrow, lymphoid organs, and extramedullary (outside of the bone marrow) sites. 
Anemia, neutropenia, thrombocytopenia, lymphadenopathy, splenomegaly, and 
hepatosplenomegaly are common clinical features. Bone pain is common among younger 
children with ALL, whose first symptom is often the onset of a limp or a refusal to walk. 
These result from the infiltration of periosrteum by leukemic cells, bone infarction, or 
expansion of the marrow cavity. Findings at initial physical examination are usually 
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unremarkable. Asymptomatic lymphadenopathy and hepatosplenomegaly occur in more 
than half of patients. The most common affected extramedullary site is the central 
nervous system (CNS). Although CNS involvement at diagnosis is relatively uncommon, 
when symptoms do occur, the clinical features can include headache, nausea and 
vomiting, lethargy, and irritability.   The common clinical features of ALL are presented 
in Table 2.1.  Other symptoms include: 
• Fatigue 
•  Paleness resulting from anemia caused by insufficient numbers of red blood 
cells.  
• Recurrent minor infections due to insufficient numbers of healthy mature white 
blood cells to fight off infection. 
• Fever without a known cause 
• Bruising, poor healing of minor cuts, uncontrolled bleeding due to insufficient 
numbers of platelets (thrombocytopenia). 
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Table. 2.1 Clinical and Laboratory Features in Childhood ALL 
 
Features % of Patients* 
Clinical Presentations  
Fever 55 
Bleeding 45 
Bone and joint pain 30 
Splenomegaly 60 
Hepatomegaly 70 
Lymphadenopathy 50 
Abdominal pain 10 
Laboratory Features  
WBC count (X 103  /μl) 
    < 10 50 
10 - 49 30 
>50 20 
Hemoglobin (g/dL)   
    < 7 43 
    7 - 11 45 
>11 12 
Platelet count ( X 103  /μl) 
    < 20 30 
    20 - 99 50 
    >100 20 
*The percentages are approximations 
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2.3. Diagnosis 
 
Several procedures can be employed to help confirm the diagnosis of ALL. These 
include a complete morphologic, immunologic, and genetic examination of the leukemic 
cells. This is essential to establish the diagnosis of acute lymphoblastic leukemia. The 
cellular hallmark of ALL, is the presence of lymphoblasts, a relatively undifferentiated 
cell with diffusely distributed nuclear chromatin, one or more nucleoli, and a basophillic 
cytoplasm. Accurate diagnosis and classification are the foundation for the successful 
treatment and biologic study of childhood acute leukemia. Modern classification of 
leukemia is based on the incorporation of morphologic findings, immunophenotype, and 
genetic abnormalies, in an attempt to define homogeneous disease subtypes that are 
clinically and biologically relevant. 
 
2.3.1. Laboratory: 
 
Clinical laboratory findings are usually unremarkable for ALL. The most 
common laboratory findings in ALL include anemia, thrombocytopenia, neutropenia, and 
leukocytosis. Other laboratory abnormalities include increased serum levels of uric acid, 
potassium, phosphorus, calcium, and lactate dehydrogenase (LDH). The degree of 
abnormality reflects the leukemic cell burden and cell lysis. Coagulation studies 
including prothrombin time (PT), activated partial thromboplastin time (aPTT), 
fibrinogen level, and D-dimer level are used to assess the degree of disseminated 
intravascular coagulation (Pui 2006). 
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2.3.2 Pathology: 
 
2.3.2.1. Morphology 
 
The morphologic diagnosis of leukemia consists of two broad steps. First, is 
establishing a general diagnosis of leukemia and second is classifying the leukemic 
process. For most patients with ALL, examination of the peripheral blood smear is 
normally sufficient to reveal leukemic lymphoblasts. Definitive diagnosis, however, 
usually requires examination of the bone marrow. According to the WHO, at least 25% 
blast cells are required to render a final diagnosis of acute leukemia. More than three 
fourths of patients, however, have more than 50% lymphoblasts in the bone marrow at 
initial presentation.  
The lymphoblasts in ALL are relatively uniform in appearance with round to oval 
to indented nuclei under a light microscope. The classic morphologic characteristics of 
ALL were established by the 1976 French-American-British (FAB) system, based on the 
microscopic features of the leukemia cells using Wright-Giemsa-stained smears. The 
FAB classification system groups ALL into three morphologic sub-groups designated L1, 
L2, and L3 (Bennett 1981). In the most common subtype L1, the lymphoblasts appear 
small in size, with scant cytoplasm, homogeneous nuclear chromatin and indistinct or 
absent nucleoli. The less common L2 sub-type presents with large cell size, more 
heterogeneous nuclear chromatin, irregular/clefting nuclear shape and prominent 
nucleoli. In practice, the majority of ALLs show a morphologic spectrum between the L1 
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and L2 subtypes, making the distinction between these categories somewhat arbitrary. 
The L3 sub-type is rarely seen. It consists of large blasts, regular nuclear features, with an 
abundant deeply basophillic cytoplasm, finely stippled chromatin, and often prominent 
nucleoli. Subsequent studies involving the immunophenotype and molecular biology of 
Burkitt lymphoma, revealed the L3 subtype was the leukemic phase of non-Hodgkin’s 
lymphoma with a mature B-cell immunophenotype (Hecht 2000). Up to 10% of 
lymphoblast cells may depart from the characteristics of each morphology sub-type. The 
FAB system lacks independent prognostic significance and thus is seldom used in current 
medical practice. 
 
 
Figure 2.2 Morphological representation of lymphoblasts. L1, left; L2, middle; L3, right. 
Source: Dept. of Pathology, The Children’s Hospital, Aurora, CO. 
 
2.3.2.2. Immunophenotype 
 
The diagnosis and treatment of ALL are depended on the recognition of a 
leukemic population, its lineage, and sometime its stage of maturation. 
Immunophenotypic studies are an essential part of the diagnostic workup of ALL; the 
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results complement morphologic studies by establishing the leukemic cell lineage, 
determining the precise stage of differentiation, and often clonality. Unlike morphologic 
features, immunophenotyping divides acute leukemia into two broad, but clinically and 
biologically meaningful, categories: B-cell ALL (B-ALL) and T-cell ALL (T-ALL). 
Several hundred monoclonal antibodies have now been assigned to over 300 
cluster differentiation (CD) groupings by the International Workshops on Leukocyte 
Differentiation Antigens (Manson 2002). A panel of antibodies is used to establish the 
diagnosis of ALL by flow cytometry. This process includes include at least one marker 
that is highly lineage specific. For example, CD19 marks the B-lineage; CD7 marks the 
T-lineage; and CD33 marks myeloid lineage cells. For the B-lineage, the panel often also 
includes PAX-5 (B-cell specific activator protein), CD20, CD22, and CD79a. A large 
percentage of B-ALL cases also show expression of CD10 (common acute lymphoblastic 
leukemia antigen). Other markers should be included for a diagnosis of pre-B cell ALL. 
These include CD34 and terminal deoxynucleotidyl transferase (TdT). The pre-B-cell 
group accounts for 80% of ALL cases and is subdivided on the basis of cytoplasmic 
immunoglobulin (Ig) expression into early pre-B-ALL (which lacks the Ig expression), 
pre-B-ALL (with expression of cytoplasmic µ chains, but without Ig light chains), and 
transitional pre-B-ALL (with cytoplasmic and weak surface expression of µ chains, 
without Ig light chain expression) (Swerdlow  2008, Li 2003). 
T-ALL is characterized by the expression of the T-lineage-associated antigens 
CD2, CD3, CD4, CD5, CD7, CD8 as well as CD10, CD34, HLA-DR, and TdT 
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(Swerdlow, 2008). The current study is focused on B cell ALL, so T-ALL will not be 
discussed further. 
 
2.4.  Genetic Features  
 
Despite relatively homogeneous morphologic and immunophenotypic features, 
ALL displays significant heterogeneity at the genetic level. The genetic characteristics 
define disease subsets with distinct biologic behavior and prognostic implications. They 
are used in the risk stratification for most modern treatment protocols. Molecular 
techniques have contributed greatly to our understanding of the pathogenesis and 
prognosis of ALL through the discovery of various common genetic alterations that occur 
in leukemic cells. The general underlying mechanisms of ALL are similar. They consist 
of aberrant proto-oncogene expression; chromosomal translocations that generate fusion 
transcripts encoding active kinases and altered transcription factors; and hyperdiploidy (≥ 
50 chromosomes per cell). These genetic alterations are linked to essential changes in  
cellular regulation and function that support the leukemic transformation of 
hematopoietic stem cells. These genetic changes enhance the cell’s capacity for self 
renewal by altering the normal cell proliferation, blocking differentiation, and promoting 
resistance to programmed cell death (apoptosis).  
 
2.4.1.  Chromosomal abnormalities   
 
ALL is associated with several chromosomal abnormalities with distinct biologic 
features that are critical for modern risk stratification. These abnormalities occur in 60 – 
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80% cases of childhood ALL. The clinicopathologic and genetic features of the major 
genetic abnormalities seen in ALL are summarized in Table 2.2. Hyperdiploidy occurs in 
almost 30% of ALL cases with favorable prognosis. Leukemia cells with hyperdiploidy 
are more susceptible to the induction of apoptosis and the accumulation of high levels of 
chemotherapeutic agents or their metabolites. This may explain the favorable outcomes 
typically observed in these patients. Trisomy (extra copies of certain chromosomes) is 
another favorable prognostic factor observed in some ALL patients. Patients whose 
leukemic cells have extra copies of chromosome 4 and 10 appear have a particularly 
favorable outcome among hyperdiploid ALL patients. The presence of trisomies 4 and 10 
has been incorporated into current treatment protocols. Approximately 1% of childhood 
ALL cases have less than 45 chromosomes, a condition termed hypodiploidy. These 
patients are at high risk for treatment failure. A significant, progressively worse outcome 
is seen for ALL patients with a decreasing numbers of chromosome. Patients with 24 – 
46 chromosomes have the worst outcome. 
 
2.4.2.  Chromosomal translocations 
 
Recurring chromosomal translocations can be detected in approximately 35 – 
40% of childhood ALL patients. In some cases, this has prognostic significance (Figure 
2.3). Currently, there is little evidence as to whether translocations are a product of errors 
in the DNA processing or are caused by external factors such as chemicals or viruses.  
However, most translocations are not sufficient to cause disease since they are more 
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common (perhaps by up to 100-fold) in the general population than their associated 
leukemias (Eguchi-Ishimae 2001, Mori 2002). 
ETV6/RUNX1  [molecular counter part of t(12;21)] is most commonly observed 
genetic lesion in childhood B-ALL (22 – 25% of cases) but it is only rarely seen in  T-cell 
ALL. This genetic lesion is thought to arise in utero in a B precursor cell during fetal 
hematopoiesis to generate a pre-leukemia clone. It has been suggested, therefore, that  
this translocation is an initiating event in B-ALL (Greaves 2006). Patients with 
ETV6/RUNX1 are generally diagnosed with B-ALL between the ages of 2 – 9 and have 
excellent treatment outcome even in the case of relapsed patients. The ETV6/RUNX1 
fusion transcript probably inhibits the transcription of the normal RUNX1 gene involved 
in the proliferation and differentiation of hematopoietic cells. This phenomenon has been 
clearly observed in clinical trials featuring intensive chemotherapy with asparaginase 
(Elspar®, Merck & CO., Inc). Interestingly, leukemic cells that express ETV6/RUNX1 are 
highly sensitive to asparaginase in vitro. 
BCR-ABL1 fusion transcripts [known as a Philadelphia chromosome, t(9;22)] are 
formed as a head-to-tail fusion of the breakpoint cluster region (BCR) gene  on 
chromosome 22 with the Abelson gene (ABL1) on chromosome 9. BCR-ABL1 encodes 
two distinct BCR-ABL1 oncoproteins, termed p210 and p190, that arise from two 
different splice sites in the BCR gene (Heisterkamp 1985). In chronic myeloid leukemia 
(CML), the BCR-ABL1 fusion transcript (p210) originates in HSC, whereas the p190 
fusion in pediatric ALL appears to arise in a lymphoid lineage precursor. It (p190) is 
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observed in approximately 3% of childhood ALL cases and it confers an unfavorable 
prognosis, especially when associated with a high White Blood Cell (WBC) count at the 
time of diagnosis. Philadelphia-positive ALL has higher frequency in older patients, 
shows poor response to prednisone, and is associated with a higher level of residual 
disease after induction chemotherapy.  
 
E2A-PBX1 fusion transcript [molecular counter part of t(1;19)] occurs in 3 – 6% 
of childhood ALL cases and exits as either a balanced or an unbalanced translocation. 
This rearrangement generates a fusion transcript that encodes a chimeric transcription 
factor from the amino-transactivation domain of E2A and the DNA-binding domain of 
PBX1 (Kamps 1990). E2A-PBX1 may contribute to leukemogenesis by binding and 
sequestering normal partners of the PBX protein, such as HOX proteins – thereby leading 
to uncontrolled cell-cycle progression (Aspland 2001). This is primarily observed in the 
pre-B ALL (i.e., cytoplasmic Ig positive). Some studies suggested that patients with a 
balanced t(1;19) translacation may do worse than patients with an unbalanced 
translocation, but this remains a point of debate due to inconsistencies between studies on 
the subject. 
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Figure 2.3 Distribution of chromosomal abnormalities in ALL. 
Data were modified from Pui and Downing to exclude the T-cell genotypes (Pui and 
Downing, 2004) 
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Table 2.2 Cytogenetic subtypes of pre-B ALL and their clinical/pathological features 
 
Cytogenetic 
Subgroup 
Frequency 
(%) 
Cytogenetic 
Abnormality 
Immunopheno- 
typic Features 
Pharmacologic 
Features 
Prognostic 
Category 
 
Hyperdiploid 
ALL 
 
27-29 
 
51 -65 
chromosomes 
 
NA 
 
Higher 
sensitivity 
to MTX, 6-
MP 
 
Favorable 
ALL with 
t(12;21) 22-25 t(12;21)(p13;q22) 
Early pre-B 
ALL 
My
Higher 
sensitivity 
+ to asparaginase 
Favorable 
ALL with 
t(1;19) 3-6 t(1;19)(q23:p13) 
Pre-B ALL 
CD9++ 
CD20- 
CD34-
/dim+ 
NA Unfavorable 
Philadelphia 
+ ALL 2-3 t(9;22)(q34;q11.2) NA NA 
Unfavorable 
High-risk 
ALL with 
t(v;11q23) 2-3 
t(4;11)(q21;q23) 
t(9;11)(p13;q23) 
Early pre-B 
ALL 
CD10- 
CD15+ 
CD65+ 
Higher 
sensitivity 
to 
cytarabine 
Unfavorable 
High-risk 
Hypodiploid 
ALL 5-6 
< 46 
chromosomes NA NA 
Unfavorable 
High-risk 
MTX, methotrexate; 6-MP, 6-mercaptopurine; My, myeloid antigens; Pre-B, precursor B; NA, not applicable. 
Adapted from Mihaela, O. “Acute Lymphoblastic Leukemia” Hematol Oncol Clin N Am 23 (2009):655-74. 
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2.5.  Prognostic Groups    
 
The National Cancer Institute (NCI) classifies childhood ALL patients into 
different treatment regimen groups. Patients between 1- 10 years old who have a white 
blood cell count of less than 50,000/μl at diagnosis are classified as standard-risk ALL. 
The remaining patients are classified as high-risk ALL. The very high-risk group is 
defined by the presence of t(9;22) or hypodiploidy. 
The prognosis of childhood ALL has improved dramatically over last five 
decades as a result of adapting therapy to the level of risk of disease relapse and continual  
reconfiguration/optimization of existing chemotherapeutic drugs.  
 
2.6.  Treatment 
 
Leukemia is a systemic disease the treatment for which is primarily based on the 
use of chemotherapy. The backbone of contemporary multi-drug chemotherapeutic 
regimens consists of three treatment stages: induction, consolidation/intensification, and 
maintenance (Figure 2.4). Successful treatment of children with ALL requires the control 
of systemic disease as well as treatment of extramedullary disease – particularly in the 
central nervous system (CNS) because systemically administered anti-leukemic drugs do 
not cross the blood-brain barrier. CNS prophylaxis therapy, therefore, is generally 
administrated during each treatment stage. The general aim of therapy in ALL is to cure 
the patient of the disease which includes: 1) to induce a clinical and hematologic 
remission; 2) to maintain remission by systemic chemotherapy and prophylactic CNS  
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therapy, and 3) to treat any complications arising from the therapy or the disease. The 
following section will discuss these approaches in greater detail. 
 
2.6.1.  Induction 
The goal in this treatment stage is to eradicate the signs and symptoms of the 
disease and to restore normal hematopoiesis. Success of this stage is marked by “clinical 
remission” (CR). A patient in CR must have no morphologic evidence of leukemia (i.e., 
<5% lymphoblasts) and a normal complete blood cell count (CBC). CR status also 
includes the absence of detectable CNS or extramedullary disease as evaluated by 
microscopic examination of the bone marrow and cerebrospinal fluid (CSF). The 
treatment regimen consists of a 3-drug (vincristine, steroids and asparaginase) or a more 
intense 4-drug (i.e., adding anthracycline to the previous mix) treatment combination. For 
patients who are at standard-risk of treatment failure, the more intense 4-drug induction 
therapy appears not to be necessary. In general, more than 95% of ALL patients will 
achieve a complete remission within the first 4 weeks after diagnosis. Day-28 bone 
marrow is evaluated morphologically for CR and its minimal residual disease (MRD) 
status. Those cases that show a very slow response to induction therapy typically receive 
an additional 2 weeks of treatment after which, a bone marrow sample is evaluated. 
Patients with induction failure (< 3%) and a high-risk status receive an additional 4-drug 
therapy. The early institution of adequate CNS prophylaxis therapy is critical for 
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eliminating CNS disease and preventing CNS relapse in patients without clinical CNS 
involvement at diagnosis. Intrathecal chemotherapy may be the most effective form of 
presymptomatic CNS therapy.  Alternately, methotrexate alone, methotrexate in 
combination with cytarabine plus hydrocortisone and/or cranial radiation may be used. 
This regimen usually started at the beginning of induction, intensified during the 
consolidation stage, and often continued throughout the maintenance stage. The CNS 
relapse rate is less than 5% for the standard-risk ALL patients treated with this regimen.  
 
2.6.2  Consolidation 
 
Early studies demonstrated that disease remission alone is insufficient to cure 
ALL. A significant amount of additional therapy is required to eradicate all malignant 
lymphoblasts – thus reducing the risk of relapse. Although the importance of this 
treatment phase is very clear, there is little consensus on the best regimens and duration 
of treatment. The most commonly used strategies include high-dose methotrexate plus 
mercaptopurine and reinduction with the same chemotherapeutic agents that had been 
administered initially. The consolidation stage also includes systemic chemotherapy 
treatment in conjunction with additional CNS sanctuary therapy. The Children’s Hospital 
of Denver belongs to the COG, and thus, its regimen consists of a combination of 6-
mercaptopurine, vincristine, corticosteroids, and methotrexate with intrathecal therapy. 
This stage usually lasts 3 months. Afterwards, a delayed intensification phase (3 months) 
with asparaginase, cyclophosphamide, doxorubicin, and cytarabine is initiated. This 
approach has significantly improved the outcome in standard-risk ALL cases. 
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2.6.3.  Maintenance 
 
For reasons that are still poorly understood, patients with ALL require 
continuation treatment to effectively prevent relapse of the disease. Although 
approximately two-thirds of ALL patients can be treated successfully with only 12 
months of therapy, prospectively indentifying those patients with any certainty is 
impossible (Toyoda 2000). Therefore, all patients receive additional therapy. The last 
stage (maintenance) of treatment for childhood ALL includes low dose daily oral 
mercaptopurine and weekly intravenous methotrexate administration. Maintenance 
therapy is the longest stage for ALL patients. It generally continues for 2- 3 years from 
the point of complete remission. In some protocols, additional pulses of vincristine and 
corticosteroids may be added. A COG randomized trial demonstrated an improved 
outcome for patients receiving vincristine/prednisone pulses. A meta-analysis of data 
from multiple clinical trials showed increased event-free survival as well. The CCG-1952 
protocol illustrates the common approach used to treat standard-risk ALL (Table 2.3). 
 
2.7.  Clinical Trial Results 
 
The clinical trials from most large cooperative groups between 1980 and 1990 
showed very similar results (Table 2.4). An improvement in ALL treatment outcome was 
obtained using very different treatment strategies, however, all of these shared a common 
approach toward treatment intensification. 
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Data from the Berlin-Frankfurt-Münster (BFM) group showed an improvement 
from a 66% successful rate in treating ALL patients in 1981 (ALL-BFM 81) to a 76% 
success rate in 1990 (ALL-BFM 90). These results demonstrated that delayed 
intensification is a crucial component of treatment.  Other information obtained from 
BFM-90 study was that certain time-points during the post-induction minimal residual 
disease evaluation helped to identify more precisely those patients at high risk for relapse. 
The COG reported marked improvement during their two successive trials (1983-1988 
and 1989-1995). Overall 10 year event-free survival (EFS) was 62% for the 1983-1988 
study and 72% for the 1989-1995 study. Delayed intensification was deemed to be the 
most crucial factor responsible for the improved therapeutic outcome. The St. Jude 
Children’s Research Hospital (SJCRH) reported that in their recent trial (Total XIII), 
early intensification of intrathecal therapy yielded a 5-year EFS of 79% (Pui 2004).  
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Table 2.3 Treatment details for CCG 1952 (Standard-risk ALL) 
 
Source: Matloub Y, et al. (2006) Blood, Vol. 108: 1165-73. 
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Table 2.4 Results of Selected Clinical Trials in Children with ALL 
Study Group Duration No. of Patients 5-Yr EFS (%) 
    
ALL-BFM 90 1990-1995 2178 78±1.0 
CCG-1800 1989-1995 5121 75±1.0 
SJCRH XIII 1991-1998 412 79.4±2.3 
NOPHO ALL-92 1992-1998 1143 77.6±1.4 
COALL-92 1992-1997 538 76.9±1.9 
 
Source:
 
 Pui and Downing (2004) 
 
Treatment outcome for childhood acute lymphoblastic leukemia has improved 
dramatically over the past three decades. The 5-year survival rate increased from 53% in 
1974-76 to 80% in 1992-99.  Figure 2.5 illustrates survival rates of successive CCG 
protocols (Hunger, 2010). These successes are in large part the result of new 
combinations and schedules of chemotherapy using establish agents rather than the result 
of new drug development. Despite this success, 25% of ALL patients ultimately relapse 
and at least 15% of patients die. Relapsed leukemia, on its own, represents the fourth 
most common malignancy in children. These numbers are greater than for children 
diagnosed with other pediatric malignancies including osteosarcoma, Ewing sarcoma and 
retinoblastoma. Thus, the overall prognosis for relapsed patients remains unsatisfactory 
despite recent improvements in treatment outcome.  
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Figure 2.5 Survival curve for CCG treatment protocols   
Source: Stephen Hunger, M.D. (personal communication) 
 
 
ALL can reappear in the bone marrow, central nervous system, testis, and other 
extramedullary “sanctuary” sites. Diagnosis is made by morphologic confirmation of 
lymphoblasts at relapse sites. Medullary ALL relapse is defined as the presence of ≥ 25% 
lymphoblasts in a bone marrow sample following the first complete remission. CNS 
relapse is defined as the presence of mophologically distinct lymphoblasts on a CSF 
cytospin with ≥ 5 blasts per microliter (µl). Testicular relapse is defined as the 
histological findings of lymphoblastic infiltration in one or both testes. The 
immunophenotypic features of relapsed ALL are largely similar to those seen in the 
diagnostic samples. Treatment of relapsed ALL varies between the different cooperative 
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groups. Typical treatment of a first relapse is often similar to the induction therapy 
employed in response to the initial diagnosis of ALL, and thus, it involves a combination 
of vincristine, a glucocorticoid, and asparaginase, plus an anthracycline, methotrexate, or 
cytarabine in varying doses and schedules. All patients who experience a second 
remission receive additional chemotherapy to maintain control of their disease. 
Hematopoietic stem cell transplantation (HSCT) is often offered to all patients with early 
bone marrow relapse. Fundamentally, both additional chemotherapy and hematopoietic 
cell transplantation are risky approaches and neither is highly effective for curing most 
ALL patients with bone marrow relapse. 
A recent Children’s Cancer Group study of 9,585 children with newly diagnosed 
ALL between 1988 and 2002 found that a total of 1,961 patients (20.5%) experienced a 
relapse involving various sites throughout the body (i.e., bone marrow: 70.8%, CNS 
21.9%, testicular 5.3%, and other extramedullary sites 3%) (Nguyen 2008). Malempati et 
al. (2007) recently summarized the data from the CCG-1952 study (NCI standard-risk 
ALL), which revealed an overall 6-year estimated EFS of 81.6%. Of the 2,174 patients 
enrolled in this study, 347 relapsed after achieving complete remission following 
induction therapy. Among the relapsed patients, 149 (42.9%) had isolated bone marrow 
relapse and 68 (19.6%) had a relapse involving both bone marrow and extramedullary 
tissues. Isolated extramedullary relapse was seen in 130 (37.5%) patients. A subsequent 
relapse event (i.e., after the first relapse) was seen in 151 patients during the 2.4 year 
follow-up period. Among the patients with a second event, 21 (13.9%) died from either 
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toxicity of the chemotherapeutic agents during reinduction therapy or reinduction failure 
leading to a major bone marrow or extramedullary relapse. A total of 41 patients (27.2%) 
died in second remission with 28 succumbing to complications from HSCT, 12 from 
chemotherapeutic agent toxicity and 1 from disease unrelated to leukemia. So far, the 
only factors predictive of survival after relapse are the site of relapse and the duration of 
the first complete remission (CR1). Risk-stratification strategies at initial diagnosis do not 
appear to be useful for predicting the outcome of this group of relapsed patients. There 
was no difference in EFS between the HSCT and chemotherapy treated patients for any 
relapse site or CR1 duration (Figure 2.6, Malempati 2007).  Management of this group of 
patients has proved extremely challenging and the long-term survival rates (i.e., 25-35%) 
for relapsed ALL patients continues to be very poor (Sadowitz 1993, Buchana 2000, 
Leahey 2000, Chessells 2003). Drug resistance in this heavily pretreated population may 
contribute to this poor response rate. 
 
Despite substantial second remission rates (>90% in some studies) and wide 
availability of hematopoietic stem cell transplantation, most children with relapse die.  
The recent COG protocols, therefore, have maximized the therapeutic limits and 
increased dose intensity in primary therapy for newly diagnosed patients with ALL. 
Increasing the dose of chemotherapeutic agents does not decrease the relapse rate. Some 
patients pay a significant price with high rates of acute and chronic toxicities. More than 
two-thirds of “cured” patients report at least one late effect, and half of them experienced 
a condition that is severe to life threatening (Landier 2008).  While the early data from  
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Figure 2.6 Comparison of second event-free survival (EFS2) after stem-cell 
transplantation and chemotherapy for bone marrow relapse. Kaplan-Meier estimate of 
with transplant vs. chemotherapy is shown. Adapted from (Malempati 2007).   
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studies of these newer protocols are encouraging, the cure rate among relapsed patients 
has remained dismal (Friedrich 2009). This underscores the importance of optimal 
primary therapy.  
More worrisome, however, is that the plateau in survival rates over the last 10 
years suggests that the limits of current treatment strategies may have been reached. 
Moreover, the current risk-stratification model cannot identify approximately half of the 
non-responding patients, and it fails to predict the individual patient who is at greatest 
risk to experience severe toxicity at drug doses that would be well tolerated by most 
patients (Donadieu 1998). The low predictive value of the conventional prognostic 
indicators (e.g., age, WBC, and karyotype) underscores the need to develop a better risk 
stratification strategy. Further improvement in treatment outcome and a reduction in drug 
toxicity will require the identification and application of new prognostic factors and 
treatment strategies. Ideally, these can used to optimize the treatment of patients as 
individuals. An in-depth understanding of the mechanisms of leukemia and host biology 
may make it possible to further refine risk stratification; thereby, resulting in the more 
efficient identification of prognostic subgroups of patients as well as appropriate 
therapeutic targets. 
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Chapter 3 
 
 Pharmacogenetics of Acute Lymphoblastic Leukemia 
 
Single nucleotide polymorphisms (SNPs) are the most frequent genetic variations. 
They constitute approximately 90% of all human genome variation; they occur every 100 
to 300 bp (Lander 2001); and, by definition, all SNPs are present in at least 1% of 
population.  
This genetic variation may play a very important role in the effectiveness and 
outcome of anticancer therapies. The chemotherapeutic drugs used to treat pediatric ALL 
have a narrow therapeutic range. Accordingly, they are associated with significant 
mortality in addition to relapse due to drug toxicity and morbidity. They are also 
associated with drug-induced second tumors. Drug-induced adverse events can be dose-
limiting factors in many cases, and this affects treatment outcome. Studies have shown 
that adjusting dosage based on drug clearance improved ALL outcomes (Evans 1997 and 
1998). Therefore, genetic variations in drug-metabolizing enzymes impact the balance 
between drug efficacy and drug toxicity – which, in turn, is likely to have an important 
impact on the treatment outcome in ALL. 
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Most research to date has been focused on the contributions of acquired genetic 
abnormalities in leukemia blasts to the long-term outcome of the disease. Much less 
attention has been given to the role of host genetic variation in determining outcome of 
ALL therapy. Some insight into the molecular and cellular biology of chemotherapy 
responders vs. non-responders, therefore, may be informative. The ultimate question 
might be: Why do some patients fail to respond positively to therapy even though they 
have the same prognostic features as those that do respond well? Genetic polymorphisms 
in the genes that encode drug metabolizing enzymes and drug targets have been shown to 
influence patient response to drugs including chemotherapeutic agents. The case of 
Thiopurine s-methyltransferase (TPMT) exemplifies the value of this type of 
pharmacogenetic research.  Studied for over 25 years and increasingly utilized at beside, 
TPMT is a drug-metabolizing enzyme that catalyses the S-methylation of cytotoxic and 
immunosupressant thiopurines such as 6-mercaptopurine (6-MP) to yield thioinosine 
monophosphate. This metabolite is then further metabolized by series of enzymes to yield 
mono, di, and triphosphates of 6-thioguanosine. These metabolites, termed 6-thioguanine 
nucleotides (TGNs), interfere with normal DNA and RNA synthesis which ultimately 
results in cell cycle arrest and apoptosis (Weinshilboum 1983, Lennard 1992, Relling 
1999).  Two major thiopurine metabolic pathways exist, oxidation catalysed by xanthine 
oxidase (XO) and methylation catalysed by TPMT (Figure 3.1) (Weinshilboum 2001 and 
2003, Krynetski 2003). The TPMT pathway is the main mechanism of thiopurine 
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metabolism in hematopoietic tissue because xanthine oxidase is not expressed in the 
hematopoietic cells (Lennard 1987).  
Large inter-individual differences in TPMT enzyme activity were described over 
30 years ago (Weinshilboum 1980). Subsequently, the genetic polymorphisms in the 
TPMT gene responsible for this phenotypic variation have been identified and 
characterized (Krynetski 1995, McLeod 2000).  More than 21 different TPMT SNPs have 
been identified which may be associated with decreased levels of TPMT enzyme activity 
and/or thiopurine-induced toxicity (Salavaggione 2005). Of those, three SNPs termed *2, 
*3A and *3C account for more than 95% of the variability in TPMT enzyme activity 
(McLeod 2000, Wang 2003) (Figure 3.2). Approximately 90% of the population is 
homozygous for the wild-type alleles (TPMT*1) and are thus are characterized as having 
“normal” enzyme activity. Approximately, 5-10% of the population are heterozygous for 
TPMT and are characterized by an intermediate level of enzyme activity. Finally, 1 in 
300 individuals carry two mutated alleles and are, therefore, severely TPMT-deficient 
(Weinshilboum 2000, Klemetsdal 1992, Yates 1997) (Figure 3.3). The most dramatic 
effect is seen in individuals with the TPMT*3A and *3B mutations which are associated 
with a virtual absence of TPMT enzyme activity. TPMT-deficient patients accumulate 
excessive amounts of the active TGNs within their leukocytes following administration 
of 6-MP and azathiopurine. This results in severe and potentially life-threatening 
hematopoietic toxicity (Evans 1991 and 2001, Relling 1999). These patients require up to 
a 90% reduction in the conventional drug dosage that is administered. Interestingly, this 
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dosage reduction does not appear to compromise the treatment outcome (Figure 3.4) 
(Evans 1991, Relling 2006). Conversely, if TPMT-deficient patients are continually 
administered the conventional dosage, they develop severe hematopoietic toxicity which 
then necessitates the discontinuation of other chemotherapeutic drugs until their absolute 
neutrophil count recovers. Thus, this adverse drug reaction can compromises the overall 
therapeutic efficacy of the treatment protocol. TPMT deficiencies have also been linked 
to an increased risk of treatment-related acute myeloid leukemia and irradiation-induced 
brain tumors (Relling 1998 and1999b). To date, TPMT remains one of the few examples 
of pharmacogenetic research that has been successfully translated from bench to the 
bedside.       
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Figure 3.1 Thiopurine Metabolism. This figure shows a simplified schematic 
representation of the metabolic pathway for thiopurine drugs. The metabolic activation 
occurs as series reactions catalysed by hypoxanthine guanine phosphoriboxyltransferase 
(HPRT), inosine monophosphate dehydrogenase, and Guanine monphosphate synthetase.  
The figure was adapted from Krynetski (2003). 
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Figure 3.2 TPMT alleles. Boxes depict exons in the TPMT gene. Grey boxes are 
untranslated regions, green boxes represent open reading frames, and red boxes represent 
exons that contain mutations. This figure is adapted from Wang (2003). 
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Figure 3.3 Frequency distribution of level of Red Blood Cell (RBC) TPMT activity 
in blood samples. The genotypes are indicated as v/v (homozygous mutant), Wt/v 
(heterozygous), and Wt/Wt (homozygous wild-type). This figure was modified from 
Wang (2003). 
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Figure 3.4 Effects of TPMT polymorphisms on the pharmacogenetics of 
mercaptopurine toxicity. a) MP given at conventional dosage. TPMT-deficient patients 
(v/v) show a tenfold higher systemic exposure to active thioguanine nucleotides (TGN) 
than do wild-type patients (wt/wt). Heterozygous patients (wt/v) show twofold higher 
TGN concentrations. The patients with higher concentrations of TGN exposure exhibit a 
significantly higher frequency of haematopoietic toxicity. b) When genotype-specific 
adjusted dosages are given (i.e., individualized therapy), similar cellular TGN 
concentrations are achieved in all patients. All three TPMT drug metabolism phenotypes 
can be treated without acute toxicity. This figure was adapted from (Cheok 2006). 
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In order to assess the possible association of functional genetic variations with 
ALL treatment outcome, a candidate gene approach was employed for the current 
research.  SNPs in genes that either mediate the disposition of chemotherapeutic agents or 
their effects may modify the risk of relapse and toxicity beyond what can be predicted 
from host and disease features alone (Relling 2001). The activity of drug-metabolizing 
enzymes determines the bioavailability and function of many chemotherapeutic agents. 
The conventional prognostic factors of age and WBC, however, have a low predictive 
value for treatment response. Unfortunately, even with large clinical trials, the ability to 
optimize treatment to the individual patient remains elusive. Major variables in predicting 
response to leukemia therapy include hereditary and acquired variability in drug 
disposition and metabolism. Although chemotherapy is the backbone of pediatric ALL 
treatment, there is a paucity of pharmacogenetic studies on the major therapeutic agents. 
In order to function effectively, most chemotherapeutic drugs undergo biotransformation 
to form reactive and cytotoxic metabolites. This biotransformation usually involves two 
stages. The first stage involves Phase I reactions which occur primarily through the 
cytochrome P450 family. Phase I reactions involve the introduction of small polar groups 
onto the parent drug by oxidation, reduction or hydrolysis. This step produces increased 
polarity in the metabolites which may then undergo further biotransformation. In the 
Phase II reactions, metabolites are conjugated with glutathione, acetate, sulfate or glycine 
to produce more water soluble compounds that can be excreted in the urine (Evans 1999).  
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3.1.  Drug-Metabolism Enzymes 
 
The cytochrome P450 enzymes comprise a superfamily of 57 genes in humans – 
the majority of which are involved in the metabolism of numerous drugs and xenobiotic 
chemicals. Cytochrome P450 enzymes contain a heme group that can accommodate up to 
6 ligands and has an absorption wavelength of 450 nm when bound to carbon-monoxide. 
The naming convention specifies family, subfamily, gene, and alleles. For example, 
CYP2D6*1 is allele 1 (wild type) within gene 6 of Subfamily D within Family 2 of the 
CYP450 superfamily (Danielson 2002). The majority of these enzymes belongs to the 
CYP1 and CYP3 families and is primarily associated with hydroxylation reactions. They 
incorporate one atom of molecular oxygen into the target substrate molecule and the 
remaining atom into a water molecule. This function facilitates the biotransformation of 
compounds that otherwise lack functional groups suitable for conjugation. Most 
chemotherapeutic drugs including cyclophosphamide, doxorubicin and vinca alkaloids 
are metabolized by cytochrome P450 enzymes. Therefore, the efficacy of many of these 
drugs is directly related to the levels of expression and activity of these enzymes.  
 
3.1.1.  CYP1A1 
CYP1A1 is an enzyme responsible for the aryl-hydrocarbon hydroxylase activity. 
It is often associated with significant enzymatic inducibility and is highly expressed in 
lymphoid cell lines (Garte 1998). This tissue specificity might correlate to an increased 
risk of carcinogenesis in leukocytes. CYP1A1 is involved in the metabolic activation of 
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several carcinogenic substances contained in tobacco products. Evidence exists that there 
is a significant influence of CYP1A1*2 on the risk of lung cancer (Vineis 2003, Taioli 
2003). Most chemotherapeutic agents involved in ALL treatment regimens are not 
directly metabolized by CYP1A1. However, synthetic glucocorticoids, which are 
important components of ALL treatment regimens, can induce the gene transcription 
which is reflected in greater catalytic activity of CYP1A1 (Bartsch 1995). Thus, if a 
patient is exposed to a carcinogenic substance (e.g., tobacco smoke), the enhanced 
enzyme activity could activate, and thus increase, the toxicity of the carcinogens resulting 
in an increased risk of leukemia relapse. An association was reported between 
CYP1A1*2A and *2B and an increased risk of developing leukemia (Sinnett 2000, Bowen 
2003). However, this association was not observed in a case-controlled study with 550 
leukemia patients (Roddam 2000). Still another study by Krajinovic et al. (2002a) 
reported that the CYP1A1*2A variant can increase the risk of leukemia and is associated 
with an unfavorable outcome in children with ALL. In their study of 320 patients treated 
with the Dana Farber Cancer Institute (DFCI) ALL protocol, sixty-four patients 
experienced an event, defined as relapse or death from disease during or after completion 
of therapy. The presence of at least one CYP1A1*2A allele was associated with an 
increased of relapse risk, Hazard Ratio (HR) = 2.3 (95% CI: 1.2-4.9). This study cohort 
included patients in the different risk groups whom were treated with various protocols. 
The current dissertation research sought to collect some data that could be evaluated for 
an association between CYP1A1*2B and the risk of disease relapse in standard-risk ALL.  
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3.1.2. CYP3A4 and CYP3A5 
The human CYP3A locus is located at 7q21.1 and consists of 4 function genes and 
3 pseudogenes (Gellner 2001). The functional genes are CYP3A4, CYP3A5, CYP3A7, and 
CYP3A43.  Of the cytochrome P450 superfamily, the CYP3A subfamily is the most 
important for drug-metabolism, accounting for 60% of P450 enzymes in the liver and 
intestines (Danielson 2002). Thus far, polymorphisms in CYP3A4 and CYP3A5 are the 
most studied in hematologic malignancies. Most chemotherapeutic agents are substrates 
for CYP3A, including vincristine, cyclophosphamide, and epidophyllotoxins (Garte, 
1998). The CYP3A4*1B polymorphism (-392A>G substitution), located in the regulatory 
region of the gene, alters the transcriptional efficiency of CYP3A4 and impacts its overall 
metabolic activity (Rebbeck 1998).  However, its relevance for drug metabolism remains 
unclear (Hesselink 2004).  On the other hand, the CYP3A5*3 and CYP3A5*6 
polymorphisms induce splice site variants that substantially decrease functional levels of 
CYP3A5 compared with the wild type alleles (Kuehl 2001). Some studies have shown a 
significant association between CYP3A4*1B/CYP3A5*3 and treatment-related leukemia, 
drug-induced toxicities, and higher etoposide clearance (Felix 1998, Kishi 2004 and 
2007). Felix reported a protective effect, Odds Ratio (OR) = 0.09 (95% CI 0.01-0.87), of 
the CYP3A4*1B allele on secondary leukemia risk in a group of 99 de novo and 30 
secondary leukemia samples. In contrast, Aplenc et al. (2003) found no statistically 
significant impact of these 3 SNPs (CYP3A4*1B, CYP3A5*3, or CYP3A5*6) on disease 
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prognosis in 533 cases of childhood ALL. An association between CYP3A4*1B and 
CYP3A5*3C polymorphisms and a decreased risk of vincristine-associated peripheral 
neuropathy, however was reported (Aplenc et al. 2003). 
   
3.1.3.  CYP2B6 
The CYP2B6 gene is located at 19q13.2 and is highly polymorphic. CYP2B6 
accounts for approximately 3-5% of total microsomal cytochrome P450 protein in the 
liver and is also expressed in intestine, kidney, and brain (Gervot 1999). Several 
polymorphisms have been reported for CYP2B6. The 1459C >T polymorphism 
(Arg487Cys), termed *5 allele, corresponds to lower CYP2B6 protein levels when 
compared with the wild-type allele (Lang 2001). Decreased enzymatic activity should 
lead to decreased active metabolites, therefore inferior response to therapy and fewer 
toxic side effects. Cyclophosphamide (CP) is a cytotoxic drug widely used in the 
treatment of a variety of malignancies. CP is a prodrug requiring bioactivation to form 
phosphamide mustard, which forms a strong bond with DNA, consequently inhibiting 
both DNA replication and cell division, and ultimately leading to cell death (Sladek 
1988).  Various cytochrome P450 enzymes have been demonstrated to be involved 4-
hydroxylation of CP in humans (illustrated in Figure 3.5). Both CYP2B6 and the 
previously discussed CYP3A4 are involved in the metabolic activation of the pro-drug 
cyclophosphamide. CYP2B6 has higher affinity for the substrate and metabolizes the CP 
by producing an active 4-hydroxy form, while CYP3A4 is responsible for the N-
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dechloroethylation of the drug to yield chloroacetaldehyde - a neurotoxin, which is 
responsible for some of the serious side effects of chemotherapy (Huang 2000). The 
primary metabolite, 4-hydroxycyclophosphamide, is in equilibrium with its open-ring 
tautomer (aldophosphamide) that undergoes chemical decomposition to form 
phosphamide mustard (a bifunctional DNA alkylator and the ultimate cytotoxic 
metabolite) and acrolein (Fleming 1997, Yu 1999) (Figure 3.5). Cyclophosphamide has a 
relatively narrow therapeutic index, and adverse effects include cardiotoxicity, 
nephrotoxicity, and myelosuppression. Studies have demonstrated wide inter-individual 
variation in the metabolism of cyclophosphamide in pediatric populations (Yule 1995). 
This makes a strong argument for studying the effect CYP2B6 polymorphisms on drug 
response in childhood ALL. 
 
3.1.4.  GST 
Glutathione-S-Transferases (GSTs) comprise a family of Phase II metabolic 
enzymes. GSTs function as dimers by catalyzing the conjugation of electrophilic 
substrates to glutathione. They are divided into eight classes, α through ө, based on their 
amino acid sequence and immunoreactivity (Hayes 1999). The GSTM1, GSTP1 and 
GSTT1 genes are members of the GST family and are located at chromosomal positions 
1p13.3, 22q11.23 and 11q13 respectively. The most common polymorphisms include 
complete deletions of the GSTM1 and/or GSTT1 gene which are termed ‘null’ alleles as 
well as two SNPs in GSTP termed GSTP1*B and GSTP1*C (Cotton 2000, 
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Figure 3.5 Metabolism of Cyclophosphamide. After cyclophosphamide administration, 
approximately 70-80% of the dose is converted into 4-hydroxycyclophosphamide 
(4OHCP) by various Cytochrome P450 enzymes including CYP2B6, 2C9, 2C19, 3A4, 
and 3A5, with CYP2B6 displaying highest 4-hydroxylase activity. 4OHCP is in 
equilibrium with its open-ring tautomer (aldophosphamide) which undergoes chemical 
decomposition to form phosphamide mustard (a DNA alkylator and the ultimate 
cytotoxic metabolite) and acrolein. 4OHCP and phosphamide mustard are detoxified by 
gluthione S-transferase (GST) to form 4-gluthionycyclophosphamise and 
digluthionycycyclophosphamide, respectively. This figure was adapted from Ekhart 
(2008). 
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Hayes 2000, Agundez 2008). GST enzymes are involved in the detoxification of various 
exogenous substances, including chemotherapeutic agents (Tew 1994). Numerous studies 
have investigated the correlation between different GST genotypes (GSTM1, GSTT1, and 
GSTP1) and the susceptibility to various cancers (e.g., lung, bladder and breast cancer) to 
treatment (Nazar-Stewart 1993, Nebert 1996).  Some of these studies have shown an 
increased risk of cancer for individuals with specific GST genotypes – an outcome 
thought to be due to lowered enzyme activity. GSTM1 and GSTT1 null genotypes lead to 
an absence of enzyme activity.  The GSTP1*B polymorphism is characterized by a single 
nucleotide 313A>G substitution in exon 5 which results in an amino acid change from 
isoleucine to valine. This mutation causes steric hindrance at the substrate-binding site of 
the enzyme thereby resulting in lower enzyme activity. Zielinska et al. (2005) recently 
assessed the role of GST variants in urinary excretion of unchanged ifosfamide and its 
side-chain metabolite. Specifically, they examined the levels of nephrotoxicity and 
neurotoxicity in 76 children who were treated with ifosfamide for different childhood 
neoplasms. They found that an individual’s response to ifosfamide was associated with 
their GSTP1 genotype. One study also demonstrated a protective effect of GST 
polymorphisms on relapse risk (Stanulla 2000). They reported a study of 64 pair of 
relapsed and non-relapsed patients from BFM-86 and BFM-90 ALL trials. The GSTM1 
and GSTT1 null genotypes were associated with a protective effect on leukemia relapse, 
OR = 0.5 (95% CI 0.23-1.07) and OR = 0.36 (95% CI 0.13-1.23). The homozygous 
GSTP1*B (i.e., Val105/Val105) genotype was noted to convey a similar protective effect, 
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OR =0.33 (95% CI 0.09-1.23). However, a similar study from St. Jude Research Hospital 
(SJCRH) did not observe a statistically significant impact for GST genotypes (Chen 
1997). They analyzed the GSTM1 and GSTT1 genotypes and disease-free survival in 161 
of 525 patients enrolled in the SJCRH Total XI, Total XII and Total XIIIa ALL 
protocols. No association between GST genotypes and relapse risk was observed, 
although a subset analysis demonstrated that the GSTM1 null genotype was associated 
with a decreased risk of CNS relapse (98% vs. 94%, p= 0.054). As a cautionary note, 
however, these studies used ALL patients with different treatment regimens; including 
high-risk protocols.    
 
 
3.2.  Drug response Pathways 
 
Methotrexate (MTX) is a major component in the intensification and maintenance 
phases of childhood ALL therapy across cooperative group trials (Chabner 2001). MTX 
is a folate antagonist which competitively inhibits dihydrofolate reductase. This leads to 
impaired regeneration of tetrahydrofolate from dihydrofolate due to a lack of folate 
coenzymes and suppression of folate-dependent syntheses of DNA and RNA precursors 
as show in the Figure 3.6. This inhibition of nucleic acid synthesis results in cellular 
death. MTX cytotoxicity is also exerted through direct inhibition of enzymes associated 
with purine and pyrimidine synthesis (Calver 1999). While highly effective in eradicating 
leukemic cells, MTX is associated with significant gastrointenstinal, hepatic, 
neurological, or hematological toxicities as well as general immune suppression. For this 
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reason, dosing based on MTX pharmacogenetics plays an important role in high-dose 
MTX therapy. High-dose infusion of MTX remains an important aspect of ALL therapy. 
The advantage of this practice in high-risk ALL is still being investigated in the current 
COG trials. It was shown to be beneficial in ALL patients with testicular disease. Several 
studies from St. Jude Children Research Hospital have demonstrated good outcome by 
individualizing the MTX dosage according to patient’s ability to clear the drug (Evans 
1997 and 1998). Dosing adjustment is still part of St. Jude Total therapeutic protocols 
today. Unfortunately, individualizing MTX dose is not always a feasible option for 
patients treated elsewhere.  
 
3.2.1.  5,10-methylenetetrahydrofolate reductase  
The 5,10-methylenetetrahydrofolate reductase (MTHFR) is located at  
chromosomal position 1p36.3 with 11 exons that span 13.5 Kb. MTHFR is a key enzyme 
for intracellular folate homeostasis and metabolism. MTHFR catalyses the irreversible 
conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate in the folate 
metabolism pathway. The 5-methyltetrahydrofolate is a major circulating form of folate 
which provides a methyl group for the methylation of homocysteine to methionine which 
is required for nucleic acid methylation (Matherly 1996). The SNPs, MTHFR 667C>T 
and 1298A>G have been associated with decreased MTHFR activity and increased levels 
of homocysteine (Frosst 1995, Weisberg 1998, van der Put 1998). A change in reduced 
folate pool, derived from MTHFR activity, may significantly affect patient response to 
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antifolate therapy. Several groups have reported a protective effect of these 
polymorphisms on leukemia susceptibility risk (Franco 2001, Alcasabas 2008). 
Conversely, reduced MTHFR activity has been linked to a higher risk of relapse and 
disease progression. Krajinovic et al. (2004) investigated the role of the MTHFR 667C>T 
and 1298A>G polymorphisms in 201 patients treated on Dana Farber Cancer Institute 
protocols for standard, high and very high risk ALL. The results showed that patients 
with the MTHFR 667T/1298A haplotype had an increased risk of relapse, HR = 2.2 (95% 
CI 1.0-4.7). Moreover, the effect of a thymidylate synthase (TYMS) triple repeat 
(associated with increased TYMS levels) combined with the MTHFR 667T/1298A 
haplotype demonstrated a highly significant reduction of EFS, HR = 9.0 (95% CI 1.0-
42.8).   Aplenc et al. (2005) presented the findings from the Children's Cancer Group 
CCG-1891 trial, a national intermediate-risk ALL study involving 137 participating 
institutions. Intermediate-risk patients between 1 and 10 years of age at diagnosis with 
initial WBC counts of <5 X 104/μl. The treatment had age-adjusted intrathecal therapy 
with weekly MTX (20 mg/m2) during the maintenance phase. An adverse event was 
defined as leukemic relapse at any site. Controls were defined as patients that remained 
with continuous remission with <5% leukemia blasts in a bone marrow aspirate. The 
study set include 520 (43%) patients who had available samples that yielded DNA 
adequate for genotyping. This sample set consisted of 124 relapsed and 396 non-relapsed 
patients. It was reported that the MTHFR 677C>T variant allele showed a statistically 
significantly association with leukemia relapse, χ2 = 4.38, P = 0.036. The association 
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remained significant (HR = 1.82 (95% CI 1.16-2.84)), when controlling for important 
covariates, and was found to be more predictive of relapse than other factors. While these 
are the two biggest studies on pediatric ALL to date, other groups have found no 
statistically significant effect (Rocha 2005, Chiusolo 2007). The wide range of results in 
the treatment response with respect to MTHFR polymorphisms may reflect differences in 
the treatment backbone of the protocol and dose adjustments made in some cases to limit 
toxicity (SJCRH protocols). 
 
3.2.2.  Thymidylate synthase 
The thymidylate synthase gene maps to chromosomal position 18p11.32 and 
contains 7 exons encoded across a 15.9 Kb genomic region (Kaneda 1990). TYMS is an 
essential enzyme for cellular proliferation. It catalyzes the transformation of 
deoxyuridine-5’-monophosphate (dUMP) to 2’-deoxythymydine-5’-monophosphate 
(dTMP) which is an essential substrate for DNA replication.  TYMS is an important 
target for methotrexate, which forms a stable complex with TYMS and folate cofactors to 
prevent DNA synthesis (Marsh 2001). The TYMS gene has a common length 
polymorphism characterized by the presence of 28-base pair tandem repeats (TR) in the 
5’ – untranslated region (5’-UTR). There are three predominant genotypes associated 
with the TYMS gene: 1) homozygous with two TR (2R/2R); 2) homozygous with three 
TR (3R/3R); and 3) heterozygous with both alleles (2R/3R). Increased TYMS mRNA 
expression and enzyme activity are associated with a greater number of tandem repeats 
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(Horie 1995, Kawakami 1999, Pullarkat 2001). Individuals who were homozygous for 
the TR (3R/3R) were found to have a 4-fold greater relapse risk (OR = 4.1 (95% CI 1.9-
9.0). This finding was confirmed in a subsequent investigation by the same research 
group at the same institution (Krajinovic 2002 and 2005). Two studies also examined the 
combined effects of multiple polymorphisms in several candidate genes in children with 
ALL who were treated using the DFCI or SJCRH Total XIIIb protocols. They 
demonstrated that patients who carried the 3R/3R genotype had a poorer outcome than 
patients with fewer TR genotypes (Costea 2003, Rocha 2005). In contrast to these results, 
however, other investigators have not been able to demonstrate similar associations 
(Lauten 2003, Pakakasama 2007).  Lauten et al. (2003) assessed the 2R/3R genotype in a 
case-controlled study of 80 patients on the ALL BFM-86 and BFM-90 protocols. All 
patients were classified as standard or intermediate risk, and received identical 
cumulative MTX doses of 20g/m2 (5 g/m2
 
 X 4 doses). They showed an OR = 1.1 (95% CI 
0.70-2.98) for 3R/3R genotype. These discordant findings are likely due to the 
heterogeneity of the study groups and their treatment protocols. Interestingly, there were 
significant differences in wild type and heterozygous frequencies between these two 
studies. One explanation for this could be due to preferential allele amplification in 
archived specimens (Miller 2002).   
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Figure 3.6 The folate pathway. This is a simplified schematic representation of the most 
important gene products involved in methotrexate (MTX) treatment response. MTX 
enters the cell through the reduced folate carrier. Its main intracellular target is 
dihydrofolate reductase (DHFR), inhibition of which results in accumulation of 
dihydrofolate (DHF) and depletion of cellular folates. MTX is a substrate for intracellular 
folypolyglutamate synthetase (FPGS), which catalyses the formation of MTXPGs, which 
then inhibits multiple target enzymes. This figure was adapted from PharmGKB (2004).  
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3.3.  t(12;21)(p12;q22) in Acute Lymphoblastic Leukemia 
The ETV6/RUNX1 (formly TEL/AML1) gene rearrangement results from a 
cryptic, balanced, reciprocal chromosomal translocation, t(12;21)(p12;q22).  This is the 
most frequently occurring genetic abnormality seen with childhood ALL (Shurtleff  1995, 
Romana 1995a) and it is associated with a favorable treatment outcome (McLean 1996, 
Rubnitz 1997 and 1999).  
The ETV6 gene (previously known as TEL) was first cloned in 1994 and is a 
member of the ETS family of transcription factors whose protein product is a nuclear 
phosphoprotein (Golub 1994 and 1997).  It was subsequently found to be fused with  
RUNX1 (previously known as AML1) in many cases of pediatric ALL (Golub 1995, 
Romana 1995b). This gene rearrangement disrupts the ETV6 gene at the N terminus and 
fuses the  helix-loop-helix (HLH) domain, inframe, to nearly all of RUNX1, including its 
DNA-binding Runt homology domain and its C-terminal transactivation region (see 
Figure 3.7). 
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Figure 3.7 Schematic representation of the TEL/AML1 gene rearrangement. Source: The 
figure was modified from Rubnitz et al. (1999). 
 
Numerous studies have been published regarding the prognostic significance of 
the ETV6/RUNX1 fusion gene with divergent results. Early studies showed excellent 
outcome. Both DFCI and St. Jude groups reported a favorable outcome for patients with 
ETV6/RUNX1 (100% 8-year EFS and 92% 5-year EFS respectively). However, reports 
from the BFM groups showed that as many as 25% of relapsed patients carried the 
ETV6/RUNX1 fusion gene (McLean 1996, Shurtleff 1995, Harbott 1997, Seeger 1998). 
Later, studies from the Pediatric Oncology Group (POG) and DFCI supported the 
excellent outcome for patients carrying ETV6/RUNX1 fusion gene (Loh 1998, Pui 2000).  
Since all treatment protocols were based on the risk-stratification strategies, the 
heterogeneity of results may reflect the intensity of the treatment protocol and the 
assignment of patients to the risk group at diagnosis. For example, nearly half of the 
ETV6/RUNX1-positive patients in the first report from the DFCI study received intensive 
therapy (McLean 1996). This difference might potentially explain the improved outcome 
in this group of patients.  Most recently, a DFCI prospective analysis of ETV6/RUNX1-
HLH ETS 
RUNT TA 
HLH RUNT TA 
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positive patients treated on their 95-01 protocol found an ETV6/RUNX1 prevalence of 
26%, with a median follow-up of 5.2 years (Loh 2006). The 5-year EFS for 
ETV6/RUNX1-positive patients was 89% compared with 80% for ETV6/RUNX1-negative 
pre-B ALL patients (P = 0.05). The 5-year Overall Survival (OS) rate was 97% among 
ETV6/RUNX1-positive ALL patients compared with an OS of 89% among 
ETV6/RUNX1-negative ALL patients (P = 0.03). This is a result which confirms their 
previous findings. 
Interestingly, among all the studies reviewed above, the unified pattern of relapse 
in ETV6/RUNX1-positive patients demonstrated that these patients tend to relapse long 
after therapy and remain sensitive to the same chemotherapy after relapse. This finding 
prompted the investigators to speculate about the origin of the relapsed clone. Using 
microsatellite markers, immunoglobulin and T-cell gene rearrangement analysis as well 
as fluorescent in situ hybridization techniques, Ford, et al. (2001) elegantly demonstrated 
that the clonal origin of two patients with late relapse was distinct from the initial 
leukemic clones despite the presence of the ETV6/RUNX1 fusion transcript in the primary 
and relapsed leukemic cells. These investigators hypothesized that in some 
ETV6/RUNX1-positive relapsed patients most, but not all, the leukemic cells are 
eradicated by the initial therapy; then a second, independent transformation event occurs 
which gives rise to new ETV6/RUNX1-positive leukemic cells. 
Most studies demonstrate that ETV6/RUNX1-positive patients have excellent 
treatment outcome compare to the ETV6/RUNX1-negative patients. Despite these 
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findings, international collaborative groups have not been able to reach a consensus 
regarding the use of a patient’s ETV6/RUNX1 status as a prognostic indicator.  
Based on the numerous supportive studies that have been reported to date, it 
would be unreasonable to completely ignore the potential for host genetic variation in to 
impact the chemo-sensitivity and treatment outcome. In the current research, therefore, 
an attempt to further evaluate the possible association between treatment outcome and 
ETV6/RUNX1 fusion transcript status in a somewhat “homogenous” group of ALL 
patients. 
 
Summary: A wealth of research data support the view that genes involved in drug 
metabolism and genes that encode drug targets influence response to therapy and disease 
outcome in patients with ALL. It is important to recognize that these genetic variations 
may significantly associate with a specific drug response phenotype in the context of one 
treatment regimen but not in other regimens for the same disease. To evaluate the role of 
variants in drug-metabolism and drug-target genes in predicting therapeutic outcome, the 
current doctoral research study was conducted with the aim of assessing potential 
associations between disease remission, disease relapse rates and polymorphisms in the 
drug metabolism genes CYP1A1, CYP2B6, CYP3A4, CYP3A5, GST, MTHFR, and TYMS. 
A total of 125 patients with standard-risk ALL treated at The Children’s Hospital, 
Aurora, Colorado served as the study population. This investigation has provided a 
unique opportunity to assess host genetic variations relative to treatment outcomes 
(specifically relapse) in a cohort of NCI-defined standard-risk ALL patients, all of whom 
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presented with defined patient and tumor characteristics and who underwent similar 
chemotherapeutic  regimens. 
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Chapter 4 
 
 Methods 
 
 
4.1.  Description of Study Population 
Children with standard risk ALL, defined as age between 1 and 10 years at 
diagnosis and initial WBC count of <5 x 104
The Center for Cancer and Blood Disorders at the Children’s Hospital of Denver 
has a COMIRB-approved research protocol to collect diagnostic peripheral and bone 
marrow samples from newly diagnosed patients with leukemia. Patient cell bank samples 
had been previously collected in a de-identified manner and leftover clinical DNA 
samples were de-identified. This study was approved by COMIRB and the University of 
Denver IRB. There are no plans for further enrollment for the current study. 
/μl, treated at The Children’s Hospital 
between 1993 and 2005 were retrospectively included in this study.  
 
4.1.1.  Inclusion criteria 
 
Patients who met the age and WBC criteria as well and for whom bone marrow or 
peripheral blood samples at initial diagnosis were available along with a record of 
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treatment outcome were included in this study. All samples were obtained from the 
COMIRB-approved cell bank in the Center for Cancer and Blood Disorders and the 
Molecular Diagnostic Laboratory at The Children’s Hospital.  Finally, to be accepted for 
inclusion in the current study, it was required that all samples had been collected per 
COMIRB 04-1041 approved protocols.  
 
4.2.  Nucleic Acid Extraction 
 Genomic DNA was extracted from peripheral blood or bone marrow aspirate 
using the Gentra PureGene Blood Kit (Gentra, Minneapolis, MN) following the 
manufacturer's instructions. Briefly, patient bone marrow (or peripheral blood) samples 
were collected in EDTA-tubes for routine clinical testing.  An aliquot of 300 μl of bone 
marrow (or peripheral blood) was incubated for 10 minutes at room temperature in 900 μl 
of RBC lysis solution.  White blood cells (WBCs) were then collected by centrifugation 
at 13,000 x g. for 20 seconds. The supernatant was carefully removed to avoid disturbing 
the WBC pellet and 600 μl of Cell Lysis Solution was added to the tube.  The WBC 
pellet was resuspended by pipetting up and down to lyse the cells. When no visible cells 
remained, 200 μl of Protein Precipitation Solution was added to the cell lysate tube. The 
tube was then vigorously vortexed for 20 seconds and centrifuged for 15 minutes at 
13,000 x g to pellet the protein. The supernatant containing the DNA was transferred to a 
clean 1.5 ml microfuge tube containing 600 μl of 100% isopropanol. The tube was 
inverted 20 – 30 times then centrifuged at 13,000 x g. for 5 minutes. The precipitated 
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DNA was then visible as a small white pellet. The supernatant was discarded and the 
pellet was washed with approximately 300 μl of 70% ethanol by inverting the tube 
several times. The tube was centrifuged at 13,000 x g for 15 minutes. The ethanol was 
poured off and the tube was left open at room temperature for 5 – 10 minutes (taking care 
not to over dry the DNA pellet). The DNA pellet was then resuspended in approximately 
50 μl of DNA Hydration Solution (10 mM Tris (pH 7.6) and 1 mM EDTA), vortexed for 
5 seconds at medium speed and then incubated at 65 0C for 15 – 30 minutes to accelerate 
rehydration. The rehydrated DNA was allowed to sit at room temperature overnight to 
ensure complete the rehydration.  The DNA concentration was measured using the 
NanoDrop spectrophotometer and all DNA samples were then diluted with DNA 
Hydration Solution to the final working concentration as 50 ng/μl. The working DNA 
solution was stored at – 70 0 
 
C until analyzed. Detailed information on the DNA 
extraction technique may be found in Appendix 1. 
4.3.  Genetic Polymorphism Detection 
 Nine SNPs and two genetic deletion/duplication mutations in the Phase I and II 
metabolism enzymes (CYP and GSP respectively) and drug-target (MTHFR and TS) 
genes were chosen for genotyping based on the important roles they played in the 
pharmacokenetics and pharmacodynamics of chemotherapeutic drugs.  TaqMan® 
(Applied Biosystems (ABI), Foster City, CA) genotyping techniques were utilized for 
SNP genotyping. Polymerase chain reaction (PCR) and argarose gel electrophoresis were 
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employed for gene deletion or duplication detection. The genetic polymorphisms content 
sequences are presented in Table 4.1. The details of the detection procedures are 
described below.   
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4.3.1.  Genotyping by TaqMan®
TaqMan
 Drug Metabolism Genotyping Assays 
® Drug Metabolism Genotyping Assays were used to detect GSPT1, 
CYP3A5, CYP2B6, and CYP1A1 polymorphisms. The assay are based on the 5’ nuclease 
chemistry for amplifying and detecting specific genetic polymorphisms in DNA samples. 
These assays were developed using ABI’s bioinformatic assay design process, and 
genomic information from public SNP databases and public genome assemblies. These 
assays are designed and optimized to work with TaqMan® Universal PCR Master Mix 
(ABI, Foster City CA) and only 3 to 20 ng of DNA is required for each reaction. Each 
assay contains sequence-specific forward and reverse primers that amplify the 
polymorphic sequence of interest; one probe labeled with a VIC® reporter dye and a non-
fluorescent quencher (NFQ) dye to detect the “Allele X” sequence and; a second probe 
labeled with a 6-FAM™ reporter dye and a NFQ dye to detect the “Allele Y” sequence. 
During PCR, each TaqMan® probe anneals specifically to its complementary sequence 
between the forward and reverse primer sites. AmpliTaq Gold® DNA polymerase extends 
the primers bound to the DNA template and cleaves only the  probe that are bound to the 
target. Cleavage separates the reporter dye from the quencher dye, resulting in increased 
fluorescence by the reporter molecule. By detecting the increase in fluorescence signal, it 
is possible to determine which alleles are present in the sample. Even single nucleotide 
mismatches between a probe and the target sequence alter the efficiency of probe binding 
to the target, which in turn reduces the amount of reporter dye cleaved from a quenched 
probe. Figure 4.1 shows the principle of this assay. A substantial increase of only VIC®  
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Figure 4.1 Principle of TaqMan® Chemistry. Allelic discrimination probes are labled 
with VIC® dye at the 5’ end of the allele 1 probe and 6-FAM™ dye at the 5’ end of allele 
2 probe. A NFQ and a MGB are linked to the 3’ end of each probes. During PCR, Taq 
DNA polymerase is more likely to displace a mismatched probe without cleaving it. 
Conversly, Taq DNA polymerase cleaves a probe that is hybridized (matched) to the 
target temple, reulting in an increased flurescence by the reporter dye. The uncleaved 
probe (mismatched) will not generate an increased fluorescence due to the presence of 
quencher dye in a close proximity. Thus, an increased fluorescence signal (6-FAM™ or 
VIC®
  
) during PCR amplification indicates which allele is present in the sample. 
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Figure 4.2 Workflow of TaqMan® genotyping. The above is a schematic representation of the 
workflow involved in the TaqMan®
 
 genotyping. From Left to right: reaction plate was prepared 
with reaction mix and template DNA, followed by PCR amplification set up with an new plate 
read (Pre-Read) was performed, then a real-time PCR was performed, followed by the post-read 
run whcih the SDS software automatically subtrates the baseline fluoresence determined at the 
pre-read and allele calls were assigned by the SDS software. 
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dye signal indicates homozygosity for Allele 1 and vise versa a substantial increase of 
only  6-FAM™ signal will indicate homozygosity for Allele 2. Heterozygosity for Allele 
1 and 2 will be represented by the increase in both VIC® and 6-FAM™
Each genotyping reaction contains 12.5 μl of 2X TaqMan
 signals. An 
“allelic discrimination experiment” is constructed according to the Applied Biosystems 
7500 “Allelic Discrimination: Getting Started Guide”. Figure 4.2 illustrates the complete 
process for an allelic discrimination experiment. 
®
Taq Gold
 Universal PCR Master 
Mix (UMM), 1.25 μl of Assay Mix (primers and probes), 10.25 μl of DNase-free water, 
and 1.0 μl of sample DNA (50 ng/μl). The UMM, Assay Mix and DNase-free water were 
combined in a microcentrifuge tube to create a master mix (MM). The MM was flicked 
and inverted several times to mix the contents. Aliquots of 24.0 μl of MM were then 
pipetted into the required number of wells on an optical 96-well plates (ABI, Foster City, 
CA). Template DNA (1 μl of 50 ng/μl stock) was then added to each well and the 
reaction plate was sealed with optical caps. Two, “no template” negative controls (Dnase-
free water) were included in each assay. The ABI 7500 Real-Time PCR System was 
slected to perform all allele discrimination experiments. This system allows real-time 
analysis of PCR, which provides for greater assay accuracyand  is helpful for 
troubleshooting. The thermal cycling conditions employed are shown below. 
®                             PCR   polymerase 
activation                          (50 cycles) 
 
HOLD Denature Anneal/Extend 
10 min at 95 o 15 sec at 92 C o 90 sec at 60 C oC 
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An Allelic Discrimination (AD) Plate Document was set up on the ABI 7500 Real-Time 
PCR System in which 6-FAM™ and VIC®
The AD data collected during the run were then analyzed by the 7500 SDS software. 
Briefly, the  raw data were converted the raw were organized in terms of fluorescence 
signal vs. filters. The SDS software plots the results from the AD run on a scatter plot of 
Allele X vs. Allele Y. Each well of the reaction plate is represented an “X” 
(Undetermined) on the plot as shown in Figure 4.3. The clustering of points can vary on 
the plot due to differences in the content of reporter dye fluorescent intensity after PCR 
amplification. Allele calls are then assigned by selecting “Automatic Allele Calling” 
under the “Analysis Setting” and then selecting the “Reanalyze” tab. Samples are then 
grouped on the plot as “Allele X”, “Allele Y”, “Both Alleles X & Y”, “Undetermined” 
and “NTC” (illustrated in Figure 4.4). The allele calls for each sample well are then 
listed in the Call column (Figure 4.5) (refer to manufacturer’s instructions for details). 
 were selected as detectors for the wildtype 
and mutant alleles, respectively. The amplification run was then performed according to 
manufacturer’s instruction (refer to manufacturer’s instructions for details). All data 
generated during the run were saved to the AD plate document specificed previously. 
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Figure 4.3 Allelic discrimination cluster plot. After a post-read, the 7500 SDS 
software display a scatter plot of Allele X vs. Allele Y with each wells 
represented by an X. The X represents the ratio of dye fluorescence intensity from 
Allele X dye and/or Allele Y dye after PCR amplification. The horizontal axis 
(Allele X) and vertical axis (Allele Y) indicate dye fluorescence intensity. 
 
 
 
 Figure 4.4 Allelic discrimination post-read plot. After 7500 SDS software 
analysed the ratio of raw fluorescence data, a post-read plot was displayed.  A genotype 
was assigned for each sample in each well according to the relative dye fluorescence 
intensity.  
 73 
 
 
Figure 4.5 Allelic discrimination genotyping reports. The post-read data can be also 
displayed as a report form. (a) displays the genotyping results in a table format, (b) 
represents the allele calls listed as the name of the dye-related probes, (c) the user-defined 
column can be used to add comments.  
 
4.3.2.  Genotyping by TaqMan®
 CYP3A4, MTHFR 667, and MTHFR 1298  polymorphisms were genotyped using  
laboratory developed assays with TaqMan
 Genotyping Assays 
® chemistry, samples handing steps and data 
analysis methods  as described in the preceeding section. The forward primer, reverse 
primer, wildtype allele probe (VIC® labeled), and mutant allele probe (6-FAM™ labeled) 
were selected from the National Cancer Institute’s SNP500 database 
(http://snp500cancer.nci.nih.gov). Primer and probe sequences are listed in Table 4.2.   
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4.3.3.  Genotyping for TYMS, GSTM1, and GSTT1 
 
 Genotyping for the TYMS tandem repeats was performed by polymerase chain 
reaction assay as previously described with modification (Hishida et al., 2003). Briefly, 
the reaction consisted of 2 μl of (50 ng/μl) genomic DNA, 2.5 μl of GeneAmp® 10X PCR 
Gold Buffer with 15 mM MgCl2 (ABI, Foster City, CA), 0.5 μl of DMSO (Sigma, MO), 
1 μl of 10 μM forward primer, 1 μl of 10 μM reverse primer, 2 μl of 2.5 mM dNTPs, 0.2 
μl of 5U/μl AmpliTaq Gold® and 16.8 μl DNase-free water.  The sequence of the forward 
primer was (5’-CGT GGC TCC TGC GTT TCC-3’) and the sequence of the reverse 
primer was (5’-GAG CCG GCC ACA GGC AT-3). Amplification was performed in a 
Veriti 96 Well Thermal Cycler (ABI, Foster City, CA) with initial denaturation at 95oC 
for 5 minutes followed by 45 cycles of 95oC for 15 seconds, 60oC for 20 seconds and 
72oC for 20 seconds. There was also a final elongation step at 72o
  
C for 10 minutes. 
Amplified PCR products were  electrophoresed through  a 3% agarose gel in 1X Tris-
Acetate-EDTA (TAE) buffer (Qiagen, Valencia, CA) and visualized with ethidium 
bromide staining to detect the 2R (210 base pair; bp) and 3R (238 bp) alleles as illustrated 
in Figure 4.6.  
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Figure 4.6 Genotyping for TYMS tandem repeats. PCR products were separated by 
electrophoresis to determine genotypes. The 2R and 3R alleles were identified by a band 
of 210 and 238 bp, respectively, as indicated. Lane M indicates a DNA ladder; Lan1 and 
2 represent 2R/2R genotype; Lane 4, 7, and 8 represent 2R/3R genotype; Lane 3, 5-6, 9-
12 represent 3R/3R genotype; Lane 13 represents no template control. 
 
                           
 
  
 
 
  
238 bp 
210 bp 
1 2 3 4 5 6 7 8 9 10 12 13 M 
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 GSTT1 and GSTM1 gene deletions, designated as null allels, were identified by 
PCR amplification as previously described (Spurdle et al., 2001), using primers located 
within the GSTT1 and GSTM1 genes to detect the presence of these gene sequences. A 
5’-untranslated region of the estrogen receptor (ER) gene was amplified as a positive 
amplification control to ensure a succesful amplification reaction. Primer sequences and 
product sizes are listed in Table 4.3. Each PCR reaction took place in a 25 μl reaction 
volume which contained 100 ng of genomic DNA, forward/reverse primers (400 nM), 
dNTPs (200 nM), 1X Gene- AMP® Gold PCR Buffer with 1.5 mM MgCl2, and 1 U 
AmpliTaq Gold® (Applied Biosystems, CA). Amplification was performed in a Veriti 96 
Well Thermal Cycler (ABI, Foster City, CA) with initial denaturation at 95oC for 5 
minutes followed by 45 cycles of 95oC for 15 seconds, 61oC for 20 seconds and 72oC for 
20 seconds. There was also a final elongation step at 72o
  
C for 10 minutes. Amplified 
PCR products were  electrophoresed through  a 3% agarose gel in 1X TAE buffer 
(Qiagen, Valencia, CA) and visualized with ethidium bromide staining to detect the 
GSTT1 and GSTM1 null alleles as illustrated in Figure 4.7. All reactions were expected 
to show amplification of the ER positive amplification control (181 bp).The absence of a 
114 bp or 131 bp fragment indicated GSTM1 or GSTT1 null genotypes, respectively. 
Patient samples showing amplification of the target PCR products were defined as having 
a non-null genotype. 
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        A           M      1      2      3      4      5      6      7      8      9     10    11    12 
 
      B 
 
      C 
 
 
Figure 4.7 Representative cases of GSTT1 and GSTM1 genotyping. Lane M indicates 
DNA ladder. (A) GSTT1 genotyping examples. Lane 3 and 4 represent null genotypes 
while the remainder of the lanes represent non-null genotypes.  (B) GSTM1 genotyping 
examples. Lanes 3, 5, 8, and 11 indicated non-null genotypes. (C) ER PCR products. 
Lane 12 was a no-template control (water) and is used to indicate the absence of 
contamination in the stock PCR reagents. Lane 4 indicates a double null genotype for 
GSTM1/GSTT1. 
 
 
 
  
181 bp 
131 bp 
114 bp 
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4.4.  Statistical Analysis 
 The primary outcome of interest in the current study was disease relapse. For 
analysis of relapse risk, cases of relapse were defined as patients who experienced 
leukemia relapse at any site. The event-free group was defined as those patients who 
remained in continous remission (<5% lymphoblasts in bone marrow aspirate). 
 The majority of the 125 patients with standard-risk ALL yielded adequate DNA 
for complete genotyping. The study set included 16 patients who experienced disease 
relapse and 109 patients in continous remission. Statistical analyses were performed with 
SAS/STAT software  (SAS Institute Inc., NC) at the Colorado Biostatistics Consortium. 
For statistical analyses, A p value less than 0.05 was considered significant. 
 Kaplan-Meier survival curve is the most common method to describe survival 
characteristics. It tracks how many individuals have not experienced the event at a given 
time or during a given time interval. The data is then plotted over the entire time of the 
study. The survival curve represents an estimated probability (Y-axis) of surviving in a 
given length of time (X-axis). This analysis allows estimation of survival over time. 
Hazard, defined as the probability of the endpoint (e.g., leukemia relapse), is a mesure of 
how rapidly the event occurs. The hazard ratio (HR) compares the hazards in two groups 
(e.g., relapse and EFS) and is calculated with its 95% confidence interval. HR is a 
estimate of relative risk of event. 
 Univariate analysis of 12 genotypes and disease relapse was performed with Chi-
square or Fisher’s exact tests to compare the genotypes frequencies in the relapse and 
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event-free groups. In order to estimate the relative risk of disease relapse, hazard ratios 
(HRs) and 95% confidence intervals (CIs) were calculated using a logistic regression 
model to evaluate the significance of differences in survival between the relapsed and 
event-free survival groups. Life table estimates were calculated by the Kaplan-Meier 
method and survival curves were generated for a graphical presentation of event-free 
survival probabilities. Survival time was defined as the time between diagnosis and the 
date of an event or last follow-up. A log-rank test was ultilized to compare time-to-
relapse values (Kaplan & Meier, 1958).  
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Chapter 5 
 
 Results 
 
 
 
 A total of 125 patients with a diagnosis of standard-risk acute lymphoblastic 
leukemia treated from 1998 through 2005 at the Center for Cancer and Blood Disorder at 
The Children’s Hospital in Denver were included in this study. Standard-risk ALL was 
defined according to NCI criteria based on age (1 – 9.99 years) and initial WBC count 
(less than 50,000/μl) at diagnosis. Genotype frequencies are shown in Table 5.2. Among 
this cohort, there were 72 (58%) males and 53 (42%) females which is comparable to the 
national frequency for standard-risk ALL. There were 16 patients who had experienced 
disease relapse and 109 patients who had remained event-free. This gives a 5-year EFS of 
87.2% which is slightly better than the national average of 81.6% (p = 0.14) (Matloub, 
2006). Patient ethnicity data were not collected because 91% of ALL patients treated at 
The Children’s Hospital in Denver are of Caucasian ethnicity. Table 5.1 shows the ethnic 
distribution among the ALL patients treated at The Children’s Hospital in Denver. 
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Table 5.1 ALL patient distribution 
Ethnic Categories Gender 
Females Males Total 
Hispanic or Latino 9 12 21 
Not Hispanic or Latino 55 74 129 
Ethnic Categories: Total of All Subjects 64 86 150 
 
Racial Categories    
American Indian/Alaska Native 2 2 4 
Asian 2 3 5 
Native Hawaiian or Other Pacific Islander 0 0 0 
Black or African-American 2 3 5 
White 58 78 136 
Racial Categories: Total of All Subjects 64 86 150 
Note: These classifications are constructed according to “Revisions to the Standards for the Classification 
of Federal Data on Race and Ethnicity” by the Office of Management and Budget (October 30, 1997). 
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Table 5.2 Genotype frequencies distribution 
 
Genotype Relapsed n (%) 
EFS 
n (%) P
1  
CYP 1A1   0.473  
AA 13 (86.7) 85 (78.7)   
AG 2   (13.3) 23 (21.3)   
GG 0   (0) 0   (0)   
CYP 2B6   0.923  
CC 13 (81.3) 85 (78.7)   
CT 3   (18.7) 21 (19.5)   
TT 0   (0) 1   (0.9)   
CYP 3A4   0.888  
AA 15 (93.8) 98 (90.7)   
AG 1   (6.2) 9   (8.4)   
GG 0   (0) 1   (0.9)   
CYP 3A5_1   0.009  
CC 15 (93.8) 108 (100)   
CT 1   (6.2) 0   (0)   
TT 0   (0) 0   (0)   
CYP 3A5_2   0.460  
AA 14 (87.5) 80 (74.1)   
AG 2   (12.5) 24 (22.2)   
GG 0   (0) 4   (3.7)   
GSTP1_1   0.502  
CC 15 (93.8) 90 (82.6)   
CT 1   (6.2) 16 (14.7)   
TT 0   (0) 3   (2.7)   
GSTP1_2   0.680  
AA 6   (37.5) 36 (33)   
AG 6   (37.5) 53 (48.6)   
GG 4   (25) 20 (18.4)   
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Table 5.2 (continued) 
 
Genotype Relapsed n (%) 
EFS 
n (%) P
1  
MTHFR 677   0.356  
CC 7   (43.8) 40 (37.4)   
CT 8   (50) 44 (41.1)   
TT 1   (6.2) 23 (21.5)   
MTHFR 1298   0.676  
AA 7   (43.8) 60 (55.5)   
AC 7   (43.8) 37 (34.3)   
CC 2   (12.5) 11 (10.2)   
GSTM1   0.144  
present 12 (75) 59 (55.7)   
null 4   (25) 47 (44.3)   
     
GSTT1   0.662  
present 14 (87.5) 89 (83.2)   
null 2   (12.5) 18 (16.8)   
     
TS  tandem 
repeat 
  0.348  
2R/2R 5   (31.3) 27 (25.2)   
2R/3R 9   (56.2) 48 (44.9)   
3R/3R 2   (12.5) 32 (29.9)   
TEL/AML1   0.096  
Present 0   (0) 16 (15.1)   
Not present 16 100) 90 (84.9)   
 
1. Chi-square test 
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 5.1.  Phase I Drug-Metabolism Enzyme Polymorphisms 
 A total of 123 patient samples were successfully genotyped for the CYP1A1 
(rs1048943) and CYP2B6 (rs3211371). Genotypic frequencies are shown in Table 5.3. 
These are comparable to the published frequencies in the NCI SNP500. Among the 123 
patient samples, 25 patients were found to be heterozygous for CYP1A1 and 2 of them 
were in the relapsed group. No individuals who were homozygous for the mutant allele 
were observed in this study cohort. There was no statistically significant difference 
between the EFS group and the disease relapsed group with regard to genotypic 
frequencies (P = 0.473, χ2
 A total of 124 patients were genotyped for CYP 3A4 (rs 2740574), CYP3A5 (rs 
10264272), and CYP3A5 (rs776746). Genotypic frequencies are comparable to published 
reports including the NCI SNP 500. There is no statistically significant difference 
between the relapsed and EFS groups for the CYP3A4 (rs2740574) and CYP3A5 
(rs776746) genotypes frequencies (p = 0.888 and 0.460, respectively). There is also no 
statistically significant difference of risk of relapse (HR = 0.67, 95% CI = 0.09 – 2.80, P 
= 0.70 and HR = 0.43, 95%CI = 0.10 – 1.90, P = 0.27 respectively). No CYP3A4 GG 
). The CYP2B6 heterozygous genotype (CT) was found in 24 
patients while the homozygous genotype (TT) was found in just 1 patient. A statistically 
significant difference was not observed in the genotype distribution between the relapsed 
group (CC, 81.3% and CT, 18.7%) and the EFS group (CC, 79.4%; CT, 19.5%; TT, 
0.9%). The TT genotype was not observed in the relapsed group. This is likely due to its 
low allele frequency. 
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genotype was observed and the AG genotype was observed in only 1 patient and that 
individual was in the relapsed group. In the EFS group, the AG genotype was found in 9 
patients and the GG genotype was found in 1 patient. 
 
5.2.  Phase II Drug-Metabolism Enzyme Polymorphisms 
 With regard to the glutathione S-transferase (GST) genotypes, four GST 
polymorphisms were analyzed.  They include 1) the coding region SNPs at codon 105  
(rs1138272) defined as GSTP1 (C > T) and codon 114 (rs1695) defined as GSTP1 (A > 
G), 2) as well as the GSTM1 and GSTT1 deletions. The homozygous deletions defined as 
GSTM1 null and GSTT1 null lead to the absence of phenotypic enzyme activity. 
 The genotypic frequencies for the current study cohort were found to be consistent with 
the published reports included in NCI SNP500. The genotype prevalence in the entire 
study population was as follow: GSTP1 (rs 1138272) CC: 84.0 %; CT: 13.6%; TT: 2.4%. 
No TT genotype was observed in the relapsed group. GSTP1 (rs1695) AA: 33.6%; AG: 
47.2%; GG: 19.2%; GSTM1 present: 58.2%; GSTM1 null: 41.8%; GSTT1 present: 83.7%; 
GSTT1 null: 16.3%. Table 5.4 shows the distribution of GSTM1, GSTT1 and GSTP1 
genotypes in the EFS and relapsed groups and the association of these genotypes with the 
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occurrence of disease relapse. In terms of the risk of disease relapse for the current study 
cohort, the GSTM1 null genotype appeared to confer a 2.5-fold protective effect 
compared to patients that were homozygous for the non-null condition.  This apparent 
protective effect, however, was not statistically significant (HR = 0.394; 95% CI = 0.127 
– 1.2254, P = 0.107). Relative to the presence of the GSTT1 gene, the GSTT1 null 
genotype was also associated with an apparent reduction in the risk of leukemia relapse. 
This apparent effect, however, was not statistically significant (HR = 0.662; 95% CI = 
0.150 – 2.915, P = 0.585). A 3-fold statistically non-significant difference in risk of 
relapse (HR = 0.341; 95% CI = 0.045 – 2.581, P = 0.298) was associated the GSTP1 
(rs1138272) CT & TT genotypes in comparison to the CC genotype. No association with 
leukemia relapse was found for the GSTP1 (rs1965) polymorphisms. The HR for the GG 
& AG genotypes compared to AA genotype was 0.828 (95% CI = 0.301 – 2.279, P = 
0.715).  
 GST enzymes exhibited broad substrate specificity toward a variety of substances 
(Tew 1994). Given the profound effect of GSTM1 and GSTT1 null genotypes (absence 
of enzyme activity), the association of GSTM1 and T1 genotype combination with the 
risk of leukemia relapse was investigated in this study cohort. Patients were grouped 
according to their genotype as either: 1) GSTM1 or T1 showed a null genotype or 2) both 
GSTM1 and T1 were present. The risk of relapse increased 2.7-fold when both GSTM1 
and GSTT1 were present compared to when either GSTM1 or GSTT1 was a null genotype 
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(HR = 2.7, 95% CI = 0.9 – 7.9, P = 0.063). This result approached but did not reach 
statistical significance.  
 
5.3.  Drug-Target Polymorphisms 
Genotype distributions for the MTHFR and TYMS enzymes, which are the 
critical components of the folate metabolic pathway, are shown in Table 5.5. Overall 
genotype frequencies were as follow: The frequencies of MTHFR genotypes involving 
the C/T polymorphism at nucleotide position 677 in the current study cohort were 38.2%, 
42.3%, and 19.5% for the CC, CT, and TT genotypes, respectively. There was no 
statistically significant association between the relapsed and EFS groups in regard to 
genotype distribution. A slightly higher TT genotype was noted for the current study 
cohort but the C and T allele frequencies were within the observed range of published 
reports. The MTHFR 677 TT genotype was observed in 6.2% and 21.5% of patients 
among the relapsed and EFS groups, respectively. This difference did not reach statistical 
significance (P = 0.356, chi-square test).  
The frequencies of MTHFR genotypes involving the A/C polymorphism at 
nucleotide position 1298 in the current study cohort were 54.0%, 35.5%, and 10.5%  for 
the AA, AC, and CC genotypes, respectively. There was no statistically significant 
difference regarding to the CC genotype distribution in the current study cohort which 
showed a frequency of  12.5% and 10.2% in the relapsed and EFS groups respectively 
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(P = 0.676, chi-squred test). The MTHFR 1298 CC genotype showed a slightly increased 
HR relative to the AA and AC genotypes (HR = 1.35, 05% CI = 0.307 – 5.962, P = 
0.689) but this did not reach statistical significance.  
The TYMS gene has a promoter enhancer region polymorphism in the 5’-
untranslated region, characterized by a double (2R) or triple (3R) 28-bp tandem repeat 
sequence. As shown in Table 5.5, the genotype frequencies of genotypes involving this 
TYMS polymorphism in the study cohort were 26.0%, 46.3%, and 27.6% for the 2R/2R, 
2R/3R, and 3R/3R genotypes, respectively. This distribution is comparable to published 
reports. Among the relapsed and EFS groups, the polymorphism distribution was 31.3% 
and 25.2% for 2R/2R, 56.2% and 44.9% for 2R/3R, and 12.4% and 29.9% for 3R/3R 
respectively. This difference was not statistically significant (P = 0.356, chi-squred test). 
The 3R/3R patients had an apparent decreased risk of leukemia relapse when compared 
to 2R/2R and 2R/3R genotypes in the study cohort (HR = 0.401, 95% CI = 0.091 – 1.767, 
P = 0.227).  This apparent difference, however,  did not reach statistical significance.  
 
5.4.  Combinational Analysis of CYP and GST Genotypes 
 CYP and GST genotypes may confer varying degrees of metabolic activities for 
chemo-theraputic agents. For this reason, the potential association between CYP-
GSTM1/T1 combinations and the risk of leukemia relapse was investigated for the 
current study cohort. Hence, the study cohort was grouped into three clinically pre-
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defined “drug exposure groups” based on their known genotypes, as: 1) High-drug 
exposure group, 2) Low drug-exposure group, and 3) Intermediate-drug exposure group. 
Table 5.6 lists the features of these groups. 
 Table 5.7 lists the “drug exposure group” with regard to the risk of leukemia 
relapse in the study cohort. Patients who were in the low-drug exposure group had a 2.2-
fold increased risk of relapse compared to the high-drug exposure group. When the high-
drug exposure group was compared to the low and other-drug exposure groups, this 
phenomenon remainded with a 2.4-fold increased risk of relapse for the low and other-
drug exposure groups compared to the high-drug exposure group. The Kaplan-Meier 
survival curves reflected these differences in the EFS. 
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Chapter 6 
 
 Discussion 
 
Acute lymphoblastic leukemia (ALL) is the most common childhood malignacy. 
Tremendous progress has been made in the therapeutic outcome of ALL over the last four 
decades.The current cure rate routinely exceeding 80% in most collaborative groups (Pui, 
2008 &2009).  Standard-risk ALL has seen 6-year event free survival reach 82% with  an 
overall survival rate of 92% (Malempati 2007, Matloub 2006). Despite these successes, 
the outcome of relapsed ALL remains poor and it is the most common cause of cancer-
related death in children. The 5-year overall survival estimate after bone marrow relapse 
is approximately 24% (Gaynon 1998, Rivera 2005). Currently there is no consensus on 
the optimal therapy for relapsed ALL patients who attain a second disease remission. As 
a result the management of relapsed ALL patients remains a major challenge for pediatric 
oncologists.  
In an attempt to discover potential markers to identify patients with ALL who 
may be at risk of leukemia relapse, a small-scale retrospective study was conducted on  
125 patients with standard-risk acute lymphoblastic leukemia who had been treated at 
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The Children’s Hospital in Denver. The rationale for the current study cohort was: 1) 
standard-risk ALL is the largest cohort of childhood acute lymphoblastic leukemia; 2) the 
cohort comprised  a single class of patients who had been uniformly treated in a single 
treatment center. This approach made it possible to determine whether interindividual 
variations in treatment response can be explained by genetic polymorphisms that 
influence drug disposition.  In this study cohort, there were 58% males and 42% females. 
Among male participants, 56% and 58% of males were in the relapsed and EFS groups, 
respectively. Gender did not present any significant difference with regard to the risk of 
leukemia relapse (P = 0.91). This finding is in agreement with all previous studies. 
 
6.1.  Phase I Drug Metabolism Enzymes 
 As described in the previous chapters, cytochrome P450 enzymes play a critical 
role in the metabolism of several chemotheraputic agents including cyclosphamide, 
doxorubicin and glucocorticoids that are commonly used in both intial induction and 
maintenance phase of pediatric ALL therapy. It had been suggested that polymorphisms 
in the genes that encode these enzymes might contribute to treatment outcome (Relling 
2001, Fleury 2004, Aplenc 2003). In the current study, no statistically significant 
association was found between an altered risk of leukemia relapse and polymorphsims in 
the CYP1A1 (rs1048943), CYP2B6 (rs3211371), CYP3A4 (rs2740574) or CYP3A5 
(rs10264272) genes. The one exception was CYP3A5 (rs776746) which was found to be 
associated with an increased risk of relapse in patients with the variant genotype (HR = 
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5.70, 95% CI = 0.743 – 43.694, P = 0.09).  No patients in the EFS group carried the 
variant alleles and only one patient in the relapsed group carried heterzygous allele (P = 
0.01). Although this allele frequency difference reached statistical significance, it should 
be noted that due to the small population of the relapsed group, this result was based on a 
single patient who carried the variant genotype. This finding should not be considered 
significant. The Kaplan-Meier survival curves shown in Figures 6.1, 6.2, 6.3, 6.4, and 
6.5 illustrate these findings.  
Aplenc et al. (2003) reported a study on the CCG-1891 standard-risk ALL trial. 
Genotypes were determined for 533 of the 1203 patients enrolled in the trial which 
included 121 relapsed patients and 412 control patients who were in remission status. In 
that study, no association was found between a risk of leukemia relapse and CYP3A4 
(rs2740574) and CYP3A5 variants (rs10264272; rs776746) (OR = 1.19, 1.02, and 0.79  
respectively). Similarly, no association between gene-gene interactions and relapse risk 
was observed either. The study did, however, detect an association between the 
CYP3A4/CYP3A5 variants and decreased toxicity.  Fleury et al. (2004) subsequently 
reported their finding of no association between CYP3A4 variants and ALL treatment 
outcome. The study included 222 patients treated on DFCI protocols 87-01, 91-01, or 95-
01. There were 33 patients who experienced a relapse and 20 who died. Rocha et al. 
(2005) reported a St. Jude study with 247 patients with newly diagnosed ALL who were 
treated on the using the Total XIIB protocol. There were 47 adverse events including 
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relapse, second malignancies, and deaths in CR. No association was observed, however, 
between the risk of relapse and CYP3A4 or CYP3A5 genotypes.  
The only positive association between CYP variants and risk of leukemia relapse 
was found in a Canadian study. Krajinovic et al. (2002a) conducted a study on 320 
pediatric ALL patients treated on DFCI protocols 87-01, 91-01, and 95-01. Sixty-four 
patients experienced an event which was defined as disease relapse or a fatal outcome 
during or after the first CR. They studied risk of relapse and functional polymorphisms in 
genes encoding drug metabolizing enzymes including CYP1A1, CYP2D6, CYP2E1. In 
this study,  the presence of CYP1A1*2A variants was associated with an increased risk of 
relapse (HR = 2.3, 95% CI = 1.1-4.9, P = 0.03). Although they noted that CYP1A1 is not 
thought to metabolize any of the chemotherapeutic agents used with the DFCI protocols. 
 In the current study, CYP2B6 variant allele frequency difference was not 
observed between the EFS group and relapsed group (19.5% vs. 18.7%  respectively, P = 
0.923). There was no effect of CYP2B6 variant on the risk of relapse (HR = 0.80, 95% CI 
= 0.23-2.80, P = 0.721). To the best of the current author’s knowledge, there are no 
reports regarding CYP2B6 polymorphisms and the risk of leukemia relapse in pediatric 
ALL.  Cyclophosphamide is given as a prodrug which must undergo activiation during 
phase I metabolism by cytochrome P450 enzymes including CYP2B6. The active 
metabolite, 4-hydroxy-cyclophosphamide, is responsible for cyclophosphamide’s 
alkylating effect (Huitema 2000). CYP2B6 should play a major role in this process 
because it has a higher affinity for the substrate than CYP2C9, CYP2C19, CYP3A4, or 
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CYP3A5 (Patterson 2002, Wall 2003). Ekhart et al. (2008) conducted a study to evaluate 
effects of genetic polymorphisms on the pharmacokinetics of cyclophosphamide in 124 
cancer patients treated with a high-dose chemotherapy (4-6 g/m2 
From the CCG-1891 study, Aplenc et al. (2003) observed that CYP3A4 and 
CYP3A5 variants were associated with decreased chemotherapeutic toxicity; specifically 
peripheral neurotoxicity. All patients were followed for more than 5 years after 
completion of therapy.  Toxicity data were collected prospectively during the study. As 
there were no toxicity data available from the study cohort employed for the current 
research, an association analysis could not be performed. 
of cyclophosphamide). 
They found no effect of polymorhphisms in the  CYP2B6, CYP2C9, CYP3A4, CYP3A5 
GSTA1, GATP1, ALDH1A1, and ALDH3A1 genes on the clearance of cyclophosphamide. 
These results may indicate the CYP2B6 variants alone are not  crucial factors affecting 
the pharpharcokinetics of cyclophosphamide. The findings from the current study 
certainly agree with Ekhart’s results.  
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Summary: It should be noted that all of the above studies have limitations. These studies 
included patients from different treatment protocols who, therefore, received different 
types of corticosteroids and dosages (even within DFCI protocols). The small samples 
sizes (drawn from patient subsets) diminish the  statistical power of the analyses that 
were performed. Another issue of concern is how representative the genotypes are since 
the DNA was extracted from the leukemic blasts rather than from from patient germline 
cells. Caution, therefore, should be taken with respect to drawing broad conclusions 
pertaining to phase I drug metabolizing enzyme polymorphisms and treatment responses. 
The findings from the current study were in agreement with some previous studies but 
not others.  
 
6.2. Phase II drug metabolism enzymes 
 Phase II drug metabolism involves conjugation of molecules to the products of 
phase I reactions to facilitate excretion. Glutathione S-transferases (GSTs) function as 
dimers by catalyzing the conjugation of mutagenic electrophilic substrates to glutathione. 
Some of the most studied GST polymorphisms including GSTP1*B (rs1695) which alters 
substrate affinity, GSTP1*C (rs1138272) which alters the catalytic activity and the 
GSTM1 and GSTT1 null genotypes - both of which lead to loss of enzyme activity. GST 
enzymes metabolize numerous chemotherapeutic agents such as glucocorticosteroids, 
vincristine, methotrexate, and cyclophosphamide. Consequently, polymorphisms in any 
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of these GST genes have significant potential to influence the treatment response of 
patients with pediatric ALL. 
 In the current study, GSTP1*C was observed in 94% of relapsed patients and 83% 
of EFS patients. This finding represents an apparent 3-fold difference in risk of leukemia 
relapse although it did not reach statistical significance (HR = 0.341, 95% CI = 0.05-2.58, 
P = 0.298). GSTP1*B did not show a significant difference between the relapse group 
and the EFS group as can be seen in Figures 6.7 and 6.8. A protective effect was 
observed, however,  with the GSTM1 and GSTT1 null alleles (HR = 0.394 and 0.662, 
respectively). Seventy-five percent of relapsed patients had the GSTM1 gene present vs. 
56% of EFS group. Thus, these genotypes appeared to be associated with a more than 2-
fold decreased in the risk of relapse. This association, however, did not reach statistical 
significance in the current study as can be seen in Figures 6.9 and 6.10. The GSTM1 and 
GSTT1 genotypes were also grouped for the purposes of statistical analysis. In the current 
study, the patients having both the GSTM1 and GSTT1 non-null genotype had a 2.7-fold 
(HR = 2.7, 95% CI=0.9-7.9, P = 0.063) increased risk of relapse relative to those patients 
who carried either a GSTM1 null or GSTT1 null genotype. This finding (Figure 6.6) was 
the strongest association in the current study. These findings are supported by the 
BFM  case-control study with 128 patients treated on ALL-BFM trails 86 and 90 
(Stanulla, 2000). In that study, the GSTM1 and GSTT1 null genotypes conferred a 2-fold 
and 2.8-fold difference in risk of relapse when compared to the presence of GSTM1 or 
GSTT1. A significant reduction in CNS relapse risk in patients who carried the GSTP1*B 
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genotype was also found although the effect was only observed in patients with 
intermediate or high risk of treatment failure. Furthermore, analyses that examined the 
risk of relapse  with the normal genotype (non protective) vs. any one, two or three 
protective genotypes was performed. These analyses demonstrated an effect with the 
addition of each protective genotype (OR = 0.53, 95% CI = 0.24-1.19, P = 0.123 and OR 
= 0.29, 95% CI = 0.06-1.37, P = 0.118 respectively) compared to the reference group 
with no low-risk genotype (GSTM1 null, GSTT1 null, and GSTP1 Val105/Val105
Rocha (2005) reported on a St. Jude Total Therapy XIIIB trial with 246 patients. 
After correcting for other risk factors such as WBC, certain translocations, day 19 
marrow, treatment arms and risk group, it was demonstrated that the GSTM1 non-null  
).  
genotype was associated with a significantly increased risk of hematologic relapse (HR = 
18.1, 95% CI=3.9-84.3, P = 0.002). Other studies, however, did not find a statistically  
significant association. Chen et al. (1997) reported on a St. Jude study of Total Therapy 
XI, XII, and XIIIA trials with 161 of 525 patients enrolled and found no significant 
inpact impact of GSTM1 and GSTT1 null genotypes on risk of leukemia relapse. 
Interestingly, in a subset analysis an apparent association was noted between the GSTM1 
null genotype and a decreased risk of CNS relapse although this did not reach statistical 
significance (HR = 0.90, 95% CI = 0.83 – 0.97, P = 0.054). 
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Thus far, the largest studies indicated no association between GST genotypes and 
risk of disease relapse. Davies (2002) studied 710 patients including 107 who had 
experienced bone marrow relapse and 25 who had experienced CNS relapse. The patients 
were from the CCG protocols 1881, 1882, 1883 and 1901 representing a total of 4087 
enrolled patients. In the analysis, an association between GSTM1 and GSTT1 null 
genotype and the risk of disease relapse was not observed. A Kaplan-Meier survival 
curve also demonstrated  the lack of a difference in the overall survival with either 
genotype. One caveat, that should be noted, however,  is that despite the large sample 
size, the genotyped patients had a lower relapse rate than the aggregate of all enrolled 
patients. Krajinovic (2002a), based on a similiar study to that described in the prior 
section on patients treated with DFCI protocols, found no association between the 
GSTM1, GSTT1 or GSTP1 genotypes and the risk of leukemia relapse. Again, however, it 
is important to emphasize that the patient population consisted of different risk groups. 
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Summary: The current study demonstrated an association between GSTM1 deletion and 
a decreased risk of disease relapse (HR = 0.39, 95% CI = 0.13-1.22, P = 0.107) in the 
pediatric standard-risk ALL patients treated at The Children’s Hospital in Denver, CO. 
When the GSTM1 and GSTT1 genotypes were combined in the analysis, there was an 
even stronger apparent association with the risk of relapse (HR = 2.73, 95% CI = 0.90-
7.90, P = 0.063). Although neither of these reached a statistical significance (P = 0.05) 
but the clinical effect was evident with 75% of patients in the relapse group  
 having the GSTM1 non-null genotype vs. 56% of patients in the EFS group. The Kaplan-
Meier survival analysis shown in Figure 6.6 also illustrates these effects. Sixty-nine 
percent of relapsed patients have both GSTM1 and GSTT1 non-null genotypes vs. 46% in 
the EFS group. With the excellent EFS rate in the standard-risk ALL, the significance of 
this finding should not be underestimated. Of course, the aforementioned studies all have 
some limitations. Most were drawn from different risk groups of patients and as a result 
the treatment regimens differed greatly. This illustrates the importance of larger 
prospective clinical trials with well defined inclusion criteria.  
 
6.3.  Drug Target Enzymes 
 Methotrexate (MTX) is a common therapeutic agent for both malignant and 
nonmalignant diseases. It plays a central role in childhood ALL across all treatment 
protocols. MTX interferes with the natural folate cycle by DHFR, TYMS, and MTHFR 
and thereby leads to a reduced folate pool, inhibition of nucleic acid synthesis, and 
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eventually cell death. Polyglutamated MTX also directly inhibits the enzymes 
synthesizing thymidylate and purine. Polymorphisms in the genes encoding those 
enzymes, therfore have the potential to influence the treatment outcome in ALL patients. 
The MTHFR gene has multiple polymorphic sites with two common non-synonymous 
variants, 677C>T and 1298A>C which are associated with reduced enzyme activity. The 
MTHFR 677 CT heterozygous genotype is associated with a 40% decrease in enzymatic 
activity while the TT homozygous genotype is associated with  a 70% reduction in 
enzymatic activity (Schwahn 2001). The TYMS gene has a 28-bp insertion in the 
promoter region. Triple repeats (3R) of this insertion have been associated with a higher 
level of TYMS expression. Since TYMS is another important target for MTX genetic 
polymorphisms in the TYMS, may influence the outcome of ALL treatment. 
In the current research, a slightly higher percentage of MTHFR 677 variant 
genotypes were observed in the study cohort, i.e., 42% CT heterozygous genotype vs. 
20% homozygous TT genotype. It is unclear why the study population employed for the 
current research had higher than anticipated frequencies of variant alleles. However the 
genotype frequencies were found to be in Hardy-Weinberg equilibrium. Some 
researchers have expressed concerns  that preferential allele amplification might result in 
an analytical genotyping error (Miller 2002). Genotyping results from the current study 
were independently confirmed by two individuals. Furthermore, the genotyping assays 
were validated throught the use of mutiple assay proficiency panels from the College of 
American Pathologists (CAP) and clinical samples (Appendix. 2). The results from the 
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current study seem to suggest a protective effect in patients with the MTHFR 677 TT 
genotype for the risk of disease relapse. This apparent effect, however,  did not reach the 
statistical significance (P = 0.221).  As illustrated in Figure 6.11, the Kaplan-Meier 
survival curve clearly shows that there is no difference between  risk of relapse with a 
MTHFR 677 TT genotype compared to either the CT or CC genotypes. Several reports 
have, however, demonstrated a protective effect of MTHFR 667 and MTHFR 1298 
polymorphisms on leukemia susceptibility risk (Franco 2001). Taub (2002) reported that 
leukemic cells with the MTHFR 677 variant alleles had an increased sensitivity (in vitro) 
to MTX. This finding suggested that patients who carried the variant genotypes should 
have a decreased risk of leukemia relapse. Most of clinical trials have appeared to 
indicate either an increased risk of relapse or decreased EFS. 
With regard to TYMS polymorphisms in the current study, a higher frequency of 
the 3R/3R genotype was found in the EFS group. Thirty-percent of patients in the EFS 
group were observed to have a 3R/3R genotype while only 13% of those in the relapsed 
group showed this genotype. The 3R/3R genotype, therfore appeared to be associated 
with a decreased risk of relapse in the current study cohort (HR = 0.40, 95% CI = 0.09-
1.77, P = 0.227), although this did not reach statistical significance. Most of recent 
studies have indicated that patients with a 3R/3R genotype were at higher risk of disease  
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relapse. Krajinovic et al. (2002b) evaluated 205 patients treated with DFCI protocols as 
described in the MTHFR section. Patients in that study with the 3R/3R genotype were 
found to have a higher risk of adverse event (OR = 4.8, 95% CI=1.1-20.1, P = 0.04). This 
effect remained when the control group contained only patients with a CR > 5 years. The 
survival analysis demonstrated similar statistical significance. 
Lauten (2003) reported their findings with patients treated on BFM protocols 86 
or 90. The increased risk of relapse that had been reported by others for the 3R/3R  
genotype was not evident in Lauten’s case-control study of 80 pediatric ALL patients 
who received the same amount of MTX (4 g/m2
During the current study, a gene expression profiling and MTX response study of 
ALL was published by St. Jude investigaters (Sorich 2008). In that study, genome-wide 
expression profiling was conducted to identify genes whose expression appeared to be 
linked to in vivo MTX response based on a drop in the WBC on day 3 following high-
dose MTX admnistration. A total of 293 patients with newly diagnosed ALL, who were 
enrolled in the Total Therapy XIII and XV protocols, were included in the study. The 
study found 48 genes and 2 cDNA clones that were stronly linked to the in vivo MTX 
response. Among those were genes involved in nucleotide metabolism (TYMS and 
). Likewise, the St. Jude Total Therapy 
XIIIB study did not observe an impact related to the 3R/3R genotype (Rocha 2005). 
Interestingly, the same group of investigators (Relling 2004) reported that patients with 
the 2R/2R genotype had a significantly increased risk for a specific adverse event; that 
being osteonecrosis of the hip (OR = 7.2, 95% CI=1.1-48.9, P = 0.044).  
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CTPS).  The study showed that low expression of TYMS was significantly associated 
with poor in vivo MTX response. Univariate hazard analysis of the risk of relapse 
produced HR of 0.60 (P = 0.008). Interestingly, other known genes involved in the folate 
metabolism pathway were not among the top 50 putatively associated genes. This finding 
suggested that de novo MTX resistance may be acquired during treatment rather than 
predisposed as was previously thought. Unfortunately RNA is not available for a similar 
analysis of the patients enrolled in the current study. 
Summary: The current study did not find that either MTHFR or TYMS variants were  
associated with an increased risk of leukemia relapse (Figure 6.12 and 6.13). On the 
contrary, the results suggested that they might have a slight protective effect against the 
risk of relapse. These discordant findings may be due to difference in study design, 
population size, and/or therapeutic regime (e.g., schedule of treatment, dosage, and 
coadministration of other therapeutic drugs). As a consequence of the heterogeneity of 
the available studies, comparisons among these studies are very difficult if not 
impossible. None of the studies mentioned the quality of the genomic DNA that was used 
in the analysis. As mentioned above, this illustrated again the importance of larger, 
prospective trials that consistently and carefully assessed study end points. Moreover, 
these trials need to collect comprehensive data on variables such as chemotherapy 
dosage, treatment compliance data, malignacy phenotype and genotype, etc.. 
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6.4.  Conclusion and Future Perspectives 
The current study provides important new information on the potential role of 
drug metabolizing enzyme polymorphisms and the risk of leukemia relapse in pediatric 
patients treated with standard-risk acute lymphoblastic leukemia at The Children’s 
Hospital in Denver, CO. This study found an association between the GSTM1 null 
genotype and a decreased risk of relapse (HR = 0.394, 95% CI=0.124-1.224, P = 0.144). 
An even greater effect was observed in terms of an increased risk of disease relapse for 
the combination of both GSTM1 and GSTT1 genes being non-null versus the presence of 
either the GSTM1 or GSTT1 null genotype (HR = 2.73, 95% CI=0.0-7.9, P = 0.063). Both 
conditions approached (but did not reach) statistical significance, however, the clinical 
impact could be more important as this appears to be the first study to demonstrate the 
effect of GSTM1 and GSTT1 null genotype with risk of leukemia relapse with standard-
risk pediatric ALL. It is important to recognize that these findings should only be applied 
in the conext of this specific treatment protocol but not other protocols. 
None of the other genetic polymorphisms in the current study showed a 
significant association with the risk of disease relapse after successful induction therapy. 
Moreover, the current study did not show a significant association between either the 
MTHFR 677 variants or the TYMS 3R/3R genotype and risk of relapse as described in 
previously reported CCG studies. This discrepancy might be explained by: 1) the limited 
scale of  the current study which may not have a sufficiently large patient population, 
(especially in the relapsed group), to detect a modest host genetic effect on the risk of 
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relapse; 2)  the presence of treatment heterogeneity may obscure modest genetic effects, 
and/or 3) the complexity of the treatment protocol which not only involves multiple 
interacting chemotherapeutic drugs but also over-the-counter medications and herbal 
supplements. Patient compliance is also an important factor. Unfortunately, the ability to 
capture and quantify these variables in most association studies is extremely limited. 
Clearly, the relatively small scale of the current study necessitates that the 
findings should be interpreted with caution. The findings from the current study may be 
protocol  specific and a genetic polymorphism that is a significant indicator of relapse in 
the current study may emerge as irrelevant in another. The improvements that have been 
achieved in pediatric ALL outcome are largely attributed to refinements in multi-drug 
chemotherapy protocols. They are administered at maximum tolerant doses for the 
pediatric population. It is therefore unlikely that we can further improve the outcome of 
ALL patients by dose-escalation of existing therapies due to the enormous toxicity that  
these drugs have on the active developmental pathways of pediatric patients. In the last 5 
years, pharmacogenomic studies have shifted to high-resolution genome-wide association 
studies in an effort to better understand the fundamental molecular biology of acute ALL 
and to identify potential markers related to treatment outcome as well as to identify novel 
therapeutic targets. Despite these advances, the pharmacogenetic of ALL remains as one 
of the most promising areas for continued investigation. The findings from the current 
study underscore the need for and the value of  prospective, large multi-institutional 
studies as a major thrust in the ongoing effort to improve the  survival of ALL patients.
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ABBREVIATIONS 
ALL  acute lymphoblastic leukemia 
AML  acute myeloid leukemia 
AZA  azathioprine 
BFM ` Berlin-Frankfurt-Munster Study Group 
BCB  comple blood count 
CCG  children’s cancer group 
CI  confidence interval 
CP  cyclophosphamide 
CR  complete remission 
Ct  cycle threshold   
CYP  cytochrome P450 
DFCI  Dana Farber Cancer Institute 
DHFR  dihydrofolate reductase 
EFS  event-free survival 
FAB  French-American-British 
6-FAM™ 6-carboxyfluorescein 
GST  glutathione s-transferase 
HSC  hematopoietic stem cell 
HPRT  hypoxanthine phosphoribosyl transferase 
HR  hazard ratio 
MGB  minor groove binding 
6MP  6-mercaptopurine 
MTHFR 5, 10-methylenetetradyfrofolate reductase 
MTX  methotrexate 
NFQ  nonfluorescent quencher 
OR  odds ratio 
POG  pediatric oncology group 
RBC  red blood cell 
SJCRH St Jude Children’s Research Hospital 
TPMT  thiopurine s-methyltransferase 
TYMS  thymidylate synthetase 
WBC  white blood cell count 
WHO  world health organization 
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Appendices 
 
 
Appendix 1. DNA  Isolation from Blood or Bone Marrow (BM) – Manual Extraction 
 
 
I. PRINCIPLE 
Red blood cells (RBCs) are first removed by preferential lysis. WBCs are then lysed to 
release lipids, nucleic acids, and proteins. The proteins and lipids are removed by high-
salt precipitation while DNA is left in solution. DNA is finally precipitated from the solution 
with isopropanol, washed with 70% ethanol and allowed to dry before re-hydrating in a 
Tris-EDTA buffer. 
 
II. SPECIMEN REQUIREMENTS 
A. Acceptable specimens: 
1. Blood or bone marrow (BM) aspirate collected in EDTA anti-coagulant 
(preferred).  Store at 2-8°C upon receipt. For best results, samples should be 
left at room temperature for no more than 24 hours prior to processing. 
2. Blood or BM collected in ACD (yellow top) or citrate (blue top) are also 
acceptable  
3. Slides from EDTA- preserved blood or BM, dried, room temp. 
B. Unacceptable specimens: 
1. Heparin is a known inhibitor of the PCR; therefore, specimens collected in 
heparin are generally not acceptable for PCR-based assays. 
2. Clotted specimens will be noted but may be accepted at the discretion of the 
technologist.  
a. If a BM sample (irreplaceable) is clotted and WBCs cannot be obtained 
from the sample, it may be processed according to the DNA Isolation 
from Fresh or Frozen Tissue Protocol.  
b. If a blood sample is clotted and WBCs cannot be obtained from the 
sample, another sample must be obtained. 
 
III. REAGENTS/EQUIPMENT/SUPPLIES 
 
A. Reagents 
1. RBC Lysis Solution, 1000 mL, Cat# 158904, QIAGEN. Store at room 
temperature. 
2. Cell Lysis Solution, 1000 mL, Cat# 158908, QIAGEN. Store at room 
temperature. 
3. Protein Precipitation Solution, 350 mL, Cat. # 158912, QIAGEN Store at 
room temperature. 
4. 2-propanol (isopropanol), molecular biology grade, 500 mL, Cat# I9516-
500ML, SIGMA. Store at room temperature. 
5. Glycogen (20 mg/ml), 100 µL, Cat# 10814-010, INVITROGEN. Store at -
20°C. 
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6. 70% Ethanol (v/v), prepared in molecular-grade water from 100% ACS/USP 
grade ethyl alcohol obtained from TCH pharmacy. Store at room 
temperature. 
7. DNA Hydration Solution, 100 mL, Cat# 1045698, QIAGEN. Store at room 
temperature. 
 
B. Equipment 
1. Centrifuges  
a. Eppendorf 5415R or equivalent benchtop microcentrifuge 
b. Beckman CPKR or equivalent floor-model centrifuge (for large-scale 
preps) 
2. Pipettors – Use only those designated for Specimen Processing, labeled as 
SP##.  Use only aerosol-resistant tips (ARTs) for specimen processing. 
3. NanoDrop ND-1000 spectrophotometer 
 
C.  Supplies 
1. 1.7 mL clear snapcap microtubes, Cat# 22-281, Genesee Scientific 
2. 15 mL BD Falcon conical polypropylene centrifuge tube, Cat# C3977-4, 
Cardinal Health 
 
 
IV. SPECIAL SAFETY PRECAUTIONS 
The reagents used in this procedure may cause eye and skin irritation.  Exposure may 
cause discomfort if swallowed or inhaled.  Read the MSDS and follow the handling 
instructions.  Wear appropriate personal protective equipment. Place all hazardous waste 
in the appropriate container. 
 
Stock volumes of alcohols used in this procedure are kept in the flammable liquid storage 
cabinet in the reagent prep room.  Smaller volumes sufficient for daily use (less than 500 
mL) may be aliquoted and stored in the specimen processing room on the benchtop. 
 
Protein Precipitation Solution is known to produce a toxic gas when mixed with bleach. 
Empty reagent bottles should not be re-used for hazardous waste. In the event of a 
spill, blot up excess with paper towels, then use water to thoroughly clean the area. 
Spray-bottle bleach may then be used as necessary for decontamination. 
 
V. QUALITY CONTROL – Individual reagents are QC’ed and results are documented.  
 
VI. PROCEDURE -  
 
NOTE: All work must be performed in the biological safety cabinet (hood) with the blower 
ON until the final DNA product is ready for hydration, at which point it may safely be 
manipulated on an open bench. 
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A. RBC lysis  
 
1. To a clear 1.7 mL microtube labeled with MDL number, add 900 µL of 
RBC Lysis Solution.  Add 300 µL of well-mixed patient specimen.  Cap 
and invert several times to mix.  Incubate a minimum of 5 minutes. Spin 
tubes for 20 seconds at 8000 rpm in the benchtop microfuge. 
2. Observe the size of the WBC pellet; it should be approximately equal to 
the “ideal” pellet size illustrated in Fig. 1 below.  If larger than the 
illustration, vortex briefly to re-suspend the cells, then divide into 2 or 
more tubes and re-spin. 
3. Pipet off the supernatant into the blood/BM waste bottle, leaving behind 
10-20 µL of residual fluid. (For Recap and vortex vigorously to resuspend 
the WBCs. 
 
 
 
                   
Figure 1. "Ideal" WBC   pellet size 
 
 
B. Cell lysis 
1. Add 600 µL of Cell Lysis Solution and pipet up and down to mix 
a. Blood or BM is processed in a 1.7 mL microtube at a 1:3 ratio with 
RBC Lysis Solution (300 µL sample and 900 µL RBC Lysis Solution). 
Scale up by using multiple microtubes, or scale down by using less 
reagent according to the specimen volume available. For most 
procedures two microtubes are preferred. 
1. Add 300 µL whole blood (or BM) to a 1.7 mL clear microtube 
labeled with the MDL number and containing 900 µL RBC Lysis 
Solution. Process 2 microtubes per sample if possible. Invert 10 
times. Incubate 5 minutes at room temperature. 
2. For slides begin at step IX.A.1.f. 
b. Centrifuge microtubes for 20 seconds at 8,000 rpm in the benchtop 
microfuge.  
1. Observe the WBC pellet, if the pellet is obscured by RBCs still, 
then remove as much of the RBC lysis supernatant as possible 
with a pipette and add another 900 µL RBC Lysis Solution. 
Vortex briefly and incubate 5 minutes at room temperature and 
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re-centrifuge as above. (Some nucleated RBCs may be present, 
particularly if the sample is a BM, and these cells may not lyse.)  
2. If the WBC pellet is clearly visible remove as much supernatant 
as possible with a pipette leaving behind the WBC pellet and 
about 10µL of the residual liquid. BM NOTE: Be sure to draw off 
all fat floating on the surface of the supernatant, otherwise it will 
contaminate the DNA in subsequent steps. 
3. Note the size of the WBC pellet to determine whether the pellet 
should be divided into more tubes due to its large size or if a 
smaller volume of cell lysis solution should be used in the 
subsequent steps due to its small size.  See Illustration I for an 
example of “good” WBC pellet size. 
4. Additionally, if more sample is available and the WBC pellet is 
small, process more blood or BM to attain enough WBCs to get 
plenty of DNA for the tests ordered. 
c. To facilitate cell lysis, vortex the microtube vigorously to resuspend the 
white cells in the residual liquid.  
d. Add 300 µL (small WBC pellet) or 600 µL (“good” WBC pellet size) of 
Cell Lysis Solution to the resuspended cells and pipette up and down 
5-10 times to lyse the WBCs. Samples are stable in Cell Lysis Solution 
for at least 18 months at room temperature. 
e. For slides, begin by washing each with ~100 µL of Cell Lysis Solution 
and use the side of a pipettor tip to scrape the material from the slide 
into a 1.7 mL clear microtube labeled with the MDL number. 
 
2. Protein Precipitation 
a. Add 100 µL (to the 300 µL volume) or 200 µL (to the 600 µL volume) of 
Protein Precipitation Solution to the cell lysate. (33 µL protein 
precipitation solution per 100 µL cell lysate). 
b. Vortex vigorously at high speed for at least 20 seconds to mix the 
Protein Precipitation Solution uniformly with the cell lysate. Watch for 
precipitation of the proteins into many red particles in the solution. The 
solution is well mixed when this appears. If this does not occur after 20 
seconds, vortex vigorously until precipitation is noted or until another 
30 seconds have elapsed, whichever comes first. Not all samples will 
appear precipitated; however the proteins will spin-down upon 
centrifugation. 
c. Centrifuge at 13,000-16,000 rpm for 3 minutes. The precipitated 
proteins will form a tight, dark brown pellet. If the pellet is not tight at 
the bottom of the microtube, centrifuge for an additional 10 minutes at 
13,000-16,000 rpm.  
 
3. DNA Precipitation 
a. Carefully pour the supernatant containing the DNA  into a 1.7 mL clear 
microtube containing 300 µL 100% Isopropanol (for samples using only 
300 µL cell lysis solution) or 600 µL 100% Isopropanol (for samples 
using 600 µL cell lysis solution). (1 to 1 ratio isopropanol and original cell 
lysis volume). 
b. Mix the sample by inverting at least 15 times. DNA may or may not be 
observed.  
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1. If DNA is observed continue inverting until the mass of DNA is a 
tighter clump rather than a loose, foamy appearing substance. 
2. If DNA is not observed add 1 µL of Glycogen and continue 
inverting another 15 times. 
c. Centrifuge at 13,000-16,000 rpm for 3 minutes if DNA was observed 
while inverting. Centrifuge for 10 minutes if DNA was not observed 
while inverting and Glycogen was added. The DNA pellet will be visible 
as a small white pellet. 
d. Pour off the supernatant, discarding it in the designated hazardous 
waste container (Alcohol), and drain the microtube briefly on clean 
absorbent paper, making sure the DNA pellet remains in the 
microtube. 
e. Add 300 µL 70% Ethanol and gently swirl the liquid over the DNA pellet 
by partial inversion 10 times to wash the DNA pellet. 
f. Centrifuge at 13,000-16,000 rpm for 3 minutes.  
g. Remove the supernatant with a pipette tip and discard in the 
designated hazardous waste container (Alcohol), leaving behind only 
the DNA. 
h. Allow DNA to dry at room temperature for 10 minutes or until there is 
no moisture in the tube. The white DNA pellet will turn translucent. 
 
4. DNA Hydration 
a. Add DNA hydration solution according to the size of the DNA pellet.  
1. If DNA was visible when precipitating (at step IX.A.3.b) add a 
minimum of 25 µL DNA hydration solution.  
2. If Glycogen was used to pellet the DNA, hydrate with a maximum 
of 12 µL DNA hydration solution. 
3. Do not over-hydrate. A sample is easy to dilute but difficult to re-
concentrate. 
4. Generally, 50 µL DNA hydration solution will achieve the desired 
0.500 µg/µL concentration if the original WBC pellet appeared as 
shown in Illustration I. 
b. If the specimen is required the same day, vortex 5 seconds at medium 
speed to mix and briefly centrifuge to collect sample at the bottom of 
the microtube before incubating at 56°C. 
c. If the specimen is to be tested on subsequent days, allow the hydrated 
sample to sit at room temperature overnight. 
d. Combine all microtubes that originated from the same sample and 
label this tube with the MDL number on a white LabPal label (i.e. 
093455 for 09-MD-3455).  
 
B. MEASUREMENT OF DNA CONCENTRATION 
1. Determine DNA concentration and purity using the NanoDrop ND1000. 
Pipette 2.0 µL of hydrated DNA onto the NanoDrop platform (as little as 1 µL 
may be used). Good quality DNA should have a 260/280 ratio between 1.7 
and 2.0.  
2. Optimal DNA concentration is between 0.1 and 0.5 µg/µl. If the concentration 
is higher than this, add additional DNA hydration solution to reach this target 
concentration.  
3. Record the DNA concentration (µg/µl) and purity on the side of the sample 
microtube. 
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4. Record DNA concentration and purity on the extraction sheet to be entered in 
the MDL database. 
5. Refer to the NanoDrop ND1000 Spectrophotometer Procedure for additional 
information. 
 
C. DNA STORAGE 
1. Store DNA at room temperature overnight to allow for complete hydration.  
2. DNA long term storage is in the -70°C freezer in a designated storage box to 
be held for testing, potential further testing and/or to be used in quality 
control testing.  
3. The adequacy of storage at –70°C is monitored by analysis of current testing 
performance using controls stored under identical conditions. 
4. Specimens are maintained in a limited access, secured area at all times. The 
Molecular Diagnostic Laboratory specimens are stored in a coded manner. 
Laboratory personnel are present when the lab is open. The laboratory has 
no public access. 
 
VII. Reference Range 
 
VIII. Method Limitations 
  
IX. REFERENCES 
A. 
 
Gentra Puregene Handbook, 4/2010, Qiagen 
X. Related Documents 
A. NanoDrop ND1000 Spectrophotometer Procedure 
XI. Attachments 
A. Document Historical Record 
B. DNA Isolation Blood BM Summary Flowchart 
 
 
 
 
Illustration I 
Ideal WBC pellet size. If much larger than this (for example 2x as large), please aliquot into 
additional clear microtubes. If much smaller than this (for example ½ as large), please use the 
smaller amount (300 µL) of Cell Lysis Solution and process more of the sample to attain more 
WBCs. 
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Appendix 2. Clinical validation: MTHFR C677T and MTHFR A1298G 
 
 
 MTHFR 677 Wild type 
 
MTHFR 677 
Variants 
 
MTHFR 677 
Wild type 7 0 
MTHFR 677 
Variants 0 26 
 
 
 
 MTHFR 677 Wild type 
 
MTHFR 677 
Variants 
 
MTHFR 677 
Wild type 2 0 
MTHFR 677 
Variants 0 6 
 
 
 MTHFR 1298 Wild type 
 
MTHFR 1298 
Variants 
 
MTHFR 1298 
Wild type 4 0 
MTHFR 1298 
Variants 0 4 
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Appendix 4. Data Coding:i
 
 
  if CYP1A1=2 then CYP1A1g=2; 
  if CYP1A1=1 then CYP1A1g=1;***reference group; 
 
  if CYP2B6=3 then CYP2B6g=2; 
  if CYP2B6=2 then CYP2B6g=2; 
  if CYP2B6=1 then CYP2B6g=1;***reference group; 
  if CYP3A4=3 then CYP3A4g=2; 
  if CYP3A4=2 then CYP3A4g=2; 
  if CYP3A4=1 then CYP3A4g=1;***reference group; 
 
  if CYP3A5_1=2 then CYP3A5_1g=2; 
  if CYP3A5_1=1 then CYP3A5_1g=1;***reference group; 
  if CYP3A5_2=1 then CYP3A5_2g=2; 
  if CYP3A5_2=2 then CYP3A5_2g=2; 
  if CYP3A5_2=3 then CYP3A5_2g=1;***reference group; 
  if GSTP1_1=3 then GSTP1_1g=2; 
  if GSTP1_1=2 then GSTP1_1g=2; 
  if GSTP1_1=1 then GSTP1_1g=1;***reference group; 
 
 
  if GSTP1_2=3 then GSTP1_2g=2; 
  if GSTP1_2=2 then GSTP1_2g=2; 
  if GSTP1_2=1 then GSTP1_2g=1;***reference group; 
 
  TSg=TS; 
 
  if MTHFR667=3 then MTHFR667g=2; 
  if MTHFR667=2 then MTHFR667g=2; 
  if MTHFR667=1 then MTHFR667g=1; ;***reference group; 
 
 
  if MTHFR1298=3 then MTHFR1298g=2; 
  if MTHFR1298=2 then MTHFR1298g=2; 
  if MTHFR1298=1 then MTHFR1298g=1;***reference group; 
 
 
  if GSTM1=2 then GSTM1g=2; 
  if GSTM1=1 then GSTM1g=1;***reference group; 
 
  if GSTT1=2 then GSTT1g=2; 
  if GSTT1=1 then GSTT1g=1;***reference group; 
 
 
 
 
if CYP3A4=1 and CYP3A5_1=1 and GSTM1=1 and GSTT1=1 then DrugExpo=3; 
 if (CYP3A4=1 or CYP3A5_1=1) and (GSTM1=2 or GSTT1=2 ) then DrugExpo=3; 
 if CYP3A4=2 and CYP3A5_1=1 and GSTM1=. and GSTT1=. then 
DrugExpo=3;***All others; 
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 if (CYP3A4=1 and CYP3A5_1=1) and (GSTM1=2 or GSTT1=2 ) then 
DrugExpo=2;***High drug exposure; 
 
 if (CYP3A4 >1 or CYP3A5_1=2) and (GSTM1=1 and GSTT1=1 ) then 
DrugExpo=1;***low drug exposure; 
 
 *** 1 vs 2; 
 
   if DrugExpo =1 then DrugExpoA=1;***low drug exposure; 
   if DrugExpo = 2 then DrugExpoA=0;***High drug exposure; 
 
 *** 1+3 vs 2; 
 if DrugExpo in (1, 3) then DrugExpoB=1;***low drug exposure + all 
others; 
 if DrugExpo = 2 then DrugExpoB=0;***High drug exposure; 
 
 
*** Drug shorter stay vs longer stay; 
 if GSTM1=1 and GSTT1=1 then DrugExpo2=1;***Drug stay shorter; 
 if GSTM1=2 or GSTT1=2 then DrugExpo2=0;***Drug stay longer; 
 
 
                                                 
i  
